Cochrane
Library

Cochrane Database of Systematic Reviews

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease (Review)

Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S

Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S.

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.

Cochrane Database of Systematic Reviews 2017, Issue 11. Art. No.: CD011373.

DOI: [10.1002/14651858.CD011373.pub2](https://doi.org/10.1002/14651858.CD011373.pub2).

www.cochranelibrary.com

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	3
BACKGROUND	5
OBJECTIVES	5
METHODS	5
RESULTS	7
Figure 1.	8
Figure 2.	9
Figure 3.	10
DISCUSSION	13
AUTHORS' CONCLUSIONS	15
ACKNOWLEDGEMENTS	15
REFERENCES	16
CHARACTERISTICS OF STUDIES	27
DATA AND ANALYSES	34
Analysis 1.1. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 1 All strokes and systemic embolic events. ...	34
Analysis 1.2. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 2 Ischaemic stroke.	35
Analysis 1.3. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 3 Haemorrhagic stroke.	35
Analysis 1.4. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 4 Major bleeding.	35
Analysis 1.5. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 5 Myocardial infarction.	36
Analysis 1.6. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 6 Minor bleeding.	36
Analysis 1.7. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 7 Gastrointestinal bleeding.	36
Analysis 1.8. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 8 Intracranial haemorrhage.	36
Analysis 1.9. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 9 All-cause mortality.	37
Analysis 2.1. Comparison 2 Direct oral anticoagulants versus warfarin: subgroup analysis for participants with CrCl 30 to 50 mL/min, Outcome 1 All strokes and systemic embolic events.	37
Analysis 2.2. Comparison 2 Direct oral anticoagulants versus warfarin: subgroup analysis for participants with CrCl 30 to 50 mL/min, Outcome 2 Major bleeding.	38
Analysis 3.1. Comparison 3 Direct oral anticoagulants versus warfarin: subgroup analysis for participants with CrCl 15 to 30 mL/min, Outcome 1 All strokes and systemic embolic events.	38
Analysis 3.2. Comparison 3 Direct oral anticoagulants versus warfarin: subgroup analysis for participants with CrCl 15 to 30 mL/min, Outcome 2 Major bleeding.	39
Analysis 4.1. Comparison 4 Direct oral anticoagulants versus warfarin: subgroup analysis for different doses of DOAC, Outcome 1 All strokes and systemic embolic events.	39
Analysis 4.2. Comparison 4 Direct oral anticoagulants versus warfarin: subgroup analysis for different doses of DOAC, Outcome 2 Major bleeding.	40
Analysis 4.3. Comparison 4 Direct oral anticoagulants versus warfarin: subgroup analysis for different doses of DOAC, Outcome 3 All-cause mortality.	40
Analysis 5.1. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 1 Epistaxis.	41
Analysis 5.2. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 2 Nasopharyngitis.	41
Analysis 5.3. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 3 Diarrhoea.	41
Analysis 5.4. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 4 Upper respiratory tract inflammation.	42
Analysis 5.5. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 5 Back pain.	42
Analysis 5.6. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 6 Cardiac failure.	42
Analysis 6.1. Comparison 6 Direct oral anticoagulants versus warfarin: fixed-effect model, Outcome 1 All strokes and systemic embolic events.	43
Analysis 6.2. Comparison 6 Direct oral anticoagulants versus warfarin: fixed-effect model, Outcome 2 Major bleeding.	43
ADDITIONAL TABLES	43
APPENDICES	44

CONTRIBUTIONS OF AUTHORS	47
DECLARATIONS OF INTEREST	47
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	47
INDEX TERMS	47

[Intervention Review]

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease

Miho Kimachi¹, Toshi A Furukawa², Kimihiko Kimachi¹, Yoshihito Goto³, Shingo Fukuma¹, Shunichi Fukuhara^{1,4}

¹Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan.

²Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan. ³Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan. ⁴Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima, Japan

Contact address: Miho Kimachi, Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, Kyoto, 606-8501, Japan. kimachi.miho.5c@kyoto-u.ac.jp.

Editorial group: Cochrane Kidney and Transplant Group.

Publication status and date: New, published in Issue 11, 2017.

Citation: Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. *Cochrane Database of Systematic Reviews* 2017, Issue 11. Art. No.: CD011373. DOI: [10.1002/14651858.CD011373.pub2](https://doi.org/10.1002/14651858.CD011373.pub2).

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Chronic kidney disease (CKD) is an independent risk factor for atrial fibrillation (AF), which is more prevalent among CKD patients than the general population. AF causes stroke or systemic embolism, leading to increased mortality. The conventional antithrombotic prophylaxis agent warfarin is often prescribed for the prevention of stroke, but risk of bleeding necessitates regular therapeutic monitoring. Recently developed direct oral anticoagulants (DOAC) are expected to be useful as alternatives to warfarin.

Objectives

To assess the efficacy and safety of DOAC including apixaban, dabigatran, edoxaban, and rivaroxaban versus warfarin among AF patients with CKD.

Search methods

We searched the Cochrane Kidney and Transplant Specialised Register (up to 1 August 2017) through contact with the Information Specialist using search terms relevant to this review. Studies in the Specialised Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal, and ClinicalTrials.gov.

Selection criteria

We included all randomised controlled trials (RCTs) which directly compared the efficacy and safety of direct oral anticoagulants (direct thrombin inhibitors or factor Xa inhibitors) with dose-adjusted warfarin for preventing stroke and systemic embolic events in non-valvular AF patients with CKD, defined as creatinine clearance (CrCl) or eGFR between 15 and 60 mL/min (CKD stage G3 and G4).

Data collection and analysis

Two review authors independently selected studies, assessed quality, and extracted data. We calculated the risk ratio (RR) and 95% confidence intervals (95% CI) for the association between anticoagulant therapy and all strokes and systemic embolic events as the primary efficacy outcome and major bleeding events as the primary safety outcome. Confidence in the evidence was assessed using GRADE.

Main results

Our review included 12,545 AF participants with CKD from five studies. All participants were randomised to either DOAC (apixaban, dabigatran, edoxaban, and rivaroxaban) or dose-adjusted warfarin. Four studies used a central, interactive, automated response system for allocation concealment while the other did not specify concealment methods. Four studies were blinded while the other was partially open-label. However, given that all studies involved blinded evaluation of outcome events, we considered the risk of bias to be low. We were unable to create funnel plots due to the small number of studies, thwarting assessment of publication bias. Study duration ranged from 1.8 to 2.8 years. The large majority of participants included in this study were CKD stage G3 (12,155), and a small number were stage G4 (390). Of 12,545 participants from five studies, a total of 321 cases (2.56%) of the primary efficacy outcome occurred per year. Further, of 12,521 participants from five studies, a total of 617 cases (4.93%) of the primary safety outcome occurred per year. DOAC appeared to probably reduce the incidence of stroke and systemic embolism events (5 studies, 12,545 participants: RR 0.81, 95% CI 0.65 to 1.00; moderate certainty evidence) and to slightly reduce the incidence of major bleeding events (5 studies, 12,521 participants: RR 0.79, 95% CI 0.59 to 1.04; low certainty evidence) in comparison with warfarin.

Authors' conclusions

Our findings indicate that DOAC are as likely as warfarin to prevent all strokes and systemic embolic events without increasing risk of major bleeding events among AF patients with kidney impairment. These findings should encourage physicians to prescribe DOAC in AF patients with CKD without fear of bleeding. The major limitation is that the results of this study chiefly reflect CKD stage G3. Application of the results to CKD stage G4 patients requires additional investigation. Furthermore, we could not assess CKD stage G5 patients. Future reviews should assess participants at more advanced CKD stages. Additionally, we could not conduct detailed analyses of subgroups and sensitivity analyses due to lack of data.

PLAIN LANGUAGE SUMMARY

Direct oral anticoagulants for prevention of stroke in atrial fibrillation patients with chronic kidney disease

What is the issue?

Chronic kidney disease (CKD) patients have an increased risk of atrial fibrillation (AF), which can often lead to stroke or systemic embolism. The conventional therapy for preventive AF is dose-adjusted warfarin, but this can increase the risk of bleeding, which necessitates regular therapeutic monitoring. Recently, direct oral anticoagulants (DOAC) have been developed as alternatives to warfarin. We reviewed the evidence on DOAC compared to warfarin for preventing stroke and systemic embolic events in AF patients with CKD.

What did we do?

We found five studies that compared the effects of DOAC (apixaban, dabigatran, edoxaban, and rivaroxaban) and dose-adjusted warfarin. The 12,545 participants in these five studies had non-valvular AF and moderate kidney impairment. These studies presented data on all composite outcomes of stroke and systematic embolic events as the primary efficacy outcome, with major bleeding events as the primary safety outcome. The median follow-up period ranged from 1.8 to 2.8 years. The evidence is accurate as of August 2017.

What did we find?

DOAC probably reduced the incidence of stroke and systemic embolic events as a primary efficacy outcome, compared to warfarin. Further, DOAC might slightly reduce the incidence of major bleeding events as a primary safety outcome, compared to warfarin.

Conclusions

This review demonstrated that DOAC are as likely as warfarin to prevent all strokes and systemic embolic events without increasing major bleeding events among AF patients with CKD. According to GRADE, the quality of the evidence was moderate for the primary efficacy outcome because of concerns with imprecision and low for the primary safety outcome because of concerns with inconsistency and imprecision. The results of this study chiefly apply to CKD stage G3 patients, since we could not assess those with CKD stage G4 or G5.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. Direct oral anticoagulants (DOAC) versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease (CKD)

DOAC versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with CKD

Patient or population: atrial fibrillation patients with CKD

Setting: Hospital-based setting

Intervention: DOAC

Comparison: Dose-adjusted warfarin

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk			
	Warfarin	DOAC			
All strokes and systemic embolic events Follow up: 1.8 years to 2.8 years	29 per 1,000	23 per 1,000 (19 to 29)	RR 0.81 (0.65 to 1.00)	12,545 (5)	⊕⊕⊕⊕ ¹ MODERATE
Major bleeding Follow up: 1.8 years to 2.8 years	55 per 1,000	43 per 1,000 (32 to 57)	RR 0.79 (0.59 to 1.04)	12,521 (5)	⊕⊕⊕⊕ ^{1 2} LOW
Myocardial infarction Follow up: 2.8 years	11 per 1,000	10 per 1,000 (5 to 21)	RR 0.92 (0.45 to 1.90)	2,740 (1)	-
Minor bleeding Follow up: 2.5 years to 2.8 years	74 per 1,000	72 per 1,000 (43 to 119)	RR 0.97 (0.58 to 1.61)	3,012 (2)	⊕⊕⊕⊕ ^{1 2} LOW
Gastrointestinal bleeding Follow up: 1.9 years to 2.8 years	17 per 1,000	24 per 1,000 (17 to 35)	RR 1.40 (0.97 to 2.01)	5,678 (2)	⊕⊕⊕⊕ ¹ MODERATE
Intracranial haemorrhage Follow up: 1.8 years to 2.8 years	14 per 1,000	6 per 1,000 (4 to 9)	RR 0.43 (0.27 to 0.69)	12,521 (5)	⊕⊕⊕⊕ ¹ MODERATE

All-cause mortality	78 per 1,000	71 per 1,000 (61 to 82)	RR 0.91 (0.78 to 1.05)	9,595 (4)	⊕⊕⊕⊕ ¹ MODERATE
Follow up: 1.8 years to 2.8 years					

***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

AF: atrial fibrillation; **CI:** confidence interval; **DOAC:** direct oral anticoagulants; **RR:** risk ratio

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Some concerns with imprecision because of the uncertain effect estimate

² Some concerns with inconsistency because of medium heterogeneity

BACKGROUND

Description of the condition

Atrial fibrillation (AF) is the most common form of sustained arrhythmia and causes irregular and rapid heart rate. Common symptoms are palpitation and chest pain; some people also experience fainting spells.

Chronic kidney disease (CKD) is an independent risk factor for AF (Go 2009). It has been reported that AF prevalence among CKD patients is much higher than the 1% to 2% prevalence in the general population (Alonso 2011; Go 2001; Nelson 2012; Stewart 2001). A recent study demonstrated AF prevalence of 16% for patients with estimated glomerular filtration rate (eGFR) of 45 mL/min or more and 20.4% prevalence for those with eGFR < 45 mL/min (Soliman 2010). CKD is defined as kidney structure or function abnormality present for more than three months, with health implications. CKD is classified into stage 1 (eGFR $\geq$ 90 mL/min); stage 2 (60 to 89 mL/min); stage 3a (45 to 59 mL/min); stage 3b (30 to 44 mL/min); stage 4 (15 to 29 mL/min); and stage 5 (< 15 mL/min) (KDIGO 2012).

CKD and AF have several risk factors in common, such as increasing age, hypertension, diabetes mellitus and other pre-existing heart diseases. Once people suffer from CKD, further multiple factors are associated with AF such as activation of the renin-angiotensin-aldosterone system, chronic inflammation, vascular calcification, and left ventricular hypertrophy (Ng 2013). AF is associated with stroke or systemic embolism, leading to increased morbidity or mortality. Stroke due to AF are attributed to the poor contractile status of the left atrium and blood stasis in the atrium that leads to thrombus formation (Watson 2009). It has been shown that reduced eGFR and proteinuria were independently associated with the incidence of thromboembolism in patients with AF after adjusting for other stroke risk factors (Go 2009).

Description of the intervention

It has been reported that anticoagulation therapy reduces the risk of thromboembolic events in AF patients with normal kidney function. The conventional antithrombotic prophylaxis agent is a vitamin K antagonist such as warfarin. Efficacy of dose-adjusted warfarin for preventing AF-related stroke has been reported to be better (risk reduction of 60%) than aspirin (20% risk reduction) (Hart 2007). However, warfarin has some limitations: it has multiple dietary interactions, especially with vitamin K, and concomitant drugs; and takes two to three days to begin working. Because warfarin has a narrow therapeutic window, and inadequate control results in haemorrhage, guidelines suggest that warfarin levels should be controlled within the range of the international normalised ratio (INR) of 2.0 to 3.0 (EHRA-EACTS 2010). In people with CKD, further warfarin-related complications may arise because risk of haemorrhage is increased (Olsen 2012). Warfarin use for people with end-stage kidney disease is particularly challenging because of the risk of serious bleeding; however, people with CKD patients in earlier stages with AF may benefit from warfarin.

Recently, direct oral anticoagulants (DOAC) have been developed as alternatives to vitamin K agonists. It has been reported that DOAC such as direct thrombin inhibitors and factor Xa inhibitors are associated with lower risks of stroke and bleeding than vitamin K agonists in people with normal kidney function (Bruins Slot 2013;

Miller 2012; Mitchell 2013). DOAC provide rapid onset of action and do not need regular monitoring because they do not interact with foods or other drugs (Eriksson 2011). Currently, major regulatory agencies (EMA 2014; FDA 2014; Health Canada 2017) have approved the DOAC for AF patients with CKD stage G3 or G4 (creatinine clearance (CrCl) or eGFR between 15 and 60 mL/min) (Table 1), but evidence supporting their use is limited (Reinecke 2013).

How the intervention might work

Warfarin indirectly interrupts the extrinsic coagulation cascade by inhibiting the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X. In contrast, factor Xa inhibitors including apixaban, edoxaban and rivaroxaban directly interrupt the activity of clotting factor Xa, which converts prothrombin to thrombin. In addition, direct thrombin inhibitors such as dabigatran also act by directly inhibiting thrombin.

Bruins Slot 2013 showed that DOAC significantly decreased the number of stroke and other systemic embolic events compared with dose-adjusted warfarin in AF patients regardless of kidney function (odds ratio (OR) 0.81, 95% confidence interval (CI) 0.72 to 0.91) and reduced major bleeding (OR 0.89, 95% CI 0.81 to 0.98).

Why it is important to do this review

The number of people with CKD and AF is rising annually. The risk for stroke or systemic thromboembolism due to AF in people with CKD is significantly higher than in those with normal kidney function (hazard ratio (HR) 1.49, 95% CI 1.38 to 1.59). All-cause mortality is also significantly higher among people with CKD (HR 2.37, 95% CI 2.30 to 2.44) (Olsen 2012) than the general population.

Although anticoagulants are frequently prescribed for CKD patients with AF to reduce the risk for stroke or systemic thromboembolic events, these agents tend to be used less often for this population than for people who do not have CKD (Olsen 2012). This finding is attributed to the fact that results of large clinical studies of anticoagulant therapy for AF among moderate to severe CKD patients are lacking, and clinicians are wary of risks of bleeding.

DOAC may be more effective and safer for people with CKD than warfarin; they show promise to reduce prevalence of stroke and systemic embolic events, and may reduce risk of bleeding.

OBJECTIVES

To assess the efficacy and safety of DOAC including apixaban, dabigatran, edoxaban, and rivaroxaban versus warfarin among AF patients with CKD.

METHODS

Criteria for considering studies for this review

Types of studies

All randomised controlled trials (RCTs) and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) comparing DOAC with warfarin were obtained. Cluster RCTs were also included if the intra-cluster correlation coefficient was reported. Cross-over studies were not included to avoid carry-over effects.

Types of participants

Eligible participants were diagnosed with non-valvular AF and moderate kidney impairment, defined as CrCl or eGFR between 15 and 60 mL/min (CKD stage G3 and G4). Non-valvular AF was diagnosed with electrocardiography. Patients were excluded if they had valvular AF, recent stroke, and conditions associated with an increased risk for bleeding.

Types of interventions

We included studies that investigated DOAC. These include apixaban, dabigatran, edoxaban, and rivaroxaban as well as any other intervention classified as DOAC. We included any dose or regimen compared with warfarin. Warfarin was to be dose-adjusted using INR.

Types of outcome measures

Primary outcomes

- Composite of all strokes and systemic embolic events
 - * All strokes: sudden focal neurologic deficit caused by cerebrovascular thrombosis, and categorised as ischaemic, haemorrhagic, or unspecified
 - * Systemic embolic events: acute vascular occlusion of an extremity or organ
- Major bleeding: reduction in haemoglobin of at least 20 g/L, and transfusion of at least two units of blood, or symptomatic bleeding in a critical area or organ.

In our protocol, we intended to distinguish the effect of DOAC on two efficacy primary outcomes: all strokes and systemic embolic events. However, all included studies reported composite outcomes for all strokes, including ischaemic and haemorrhagic stroke and systemic embolic events; we therefore assessed these as one composite outcome.

Secondary outcomes

- Myocardial infarction (MI): diagnosis based on electrocardiographic changes, elevation of enzymes or confirmed during post-mortem examination
- Minor bleeding: non-major clinically relevant bleeding
- Gastrointestinal (GI) bleeding
- Intracranial haemorrhage: all intracerebral, subdural, epidural and subarachnoid haemorrhage
- All-cause mortality: death from any cause (vascular and non-vascular)
- Vascular death: death due to stroke (both ischaemic and haemorrhagic), heart disease, haemorrhage and sudden deaths of unknown causes.

Search methods for identification of studies

Electronic searches

We searched the [Cochrane Kidney and Transplant Specialised Register](#) (up to 1 August 2017) through contact with the Information Specialist using search terms relevant to this review. The Cochrane kidney and Transplant Specialised Register contains studies identified from the following sources.

1. Monthly searches of the Cochrane Central Register of Controlled Trials CENTRAL

2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.

Studies contained in the Specialised Register were identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, were available in the Specialised Register section of information about [Cochrane Kidney and Transplant](#).

See [Appendix 1](#) for search terms used in strategies for this review.

Searching other resources

1. Reference lists of review articles, relevant studies, and clinical practice guidelines.
2. Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies.
3. We also searched reference lists of the identified studies and contacted the pharmaceutical companies.

Data collection and analysis

Selection of studies

The search strategy described was used to obtain titles and abstracts of studies that might be relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable; however, studies and reviews that might include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts, and if necessary, the full text of these studies to determine which satisfy our inclusion criteria.

Data extraction and management

Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non-English or non-Japanese language journals was translated before assessment. Where more than one publication of one study exists, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancy between published versions was highlighted.

Assessment of risk of bias in included studies

The following items were independently assessed by two authors using the risk of bias assessment tool ([Higgins 2011](#)) (see [Appendix 2](#)).

- Was there adequate sequence generation (selection bias)?
- Was allocation adequately concealed (selection bias)?
- Was knowledge of the allocated interventions adequately prevented during the study?
 - * Participants and personnel (detection bias)
 - * Outcome assessors (performance bias)

- Were incomplete outcome data adequately addressed (attrition bias)?
- Were reports of the study free of suggestion of selective outcome reporting (reporting bias)?
- Was the study apparently free of other problems that could put it at a risk of bias?

Measures of treatment effect

For dichotomous outcomes (e.g. stroke, bleeding), results were expressed as risk ratio (RR) with 95% CI. Where continuous scales of measurement were used to assess the effects of treatment, the mean difference (MD) were used, or the standardised mean difference (SMD) if different scales had been used.

Unit of analysis issues

RCTs with multiple intervention groups were included. Each intervention group was compared to the single control group.

Dealing with missing data

Any further information required from the original author was requested by written correspondence (e.g. emailing to corresponding authors) and any relevant information obtained in this manner was included in the review. Evaluation of important numerical data such as screened, randomised patients as well as intention-to-treat (ITT), as-treated and per-protocol (PP) population were carefully performed. Attrition rates, for example drop-outs, losses to follow-up and withdrawals were investigated. Issues of missing data and imputation methods (for example, last-observation-carried-forward) were critically appraised ([Higgins 2011](#)).

Assessment of heterogeneity

Heterogeneity was analysed using a χ^2 test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I^2 test ([Higgins 2003](#)). I^2 values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.

Assessment of reporting biases

If possible, funnel plots were used to assess for the potential existence of small study bias ([Higgins 2011](#)).

Data synthesis

Data were pooled using the random-effects model but the fixed-effects model was also be used to ensure robustness of the model chosen and susceptibility to outliers.

Subgroup analysis and investigation of heterogeneity

Subgroup analysis was used to explore possible sources of heterogeneity (e.g. participants, interventions and study quality). Heterogeneity among participants could be related to age, history of previous stroke and baseline stroke risk factors (assessed by CHADS₂ score) ([Gage 2001](#)). CKD stages were also assessed.

Heterogeneity in treatments could be related to dose and duration of therapy, subtype of DOAC, and concomitant use of antiplatelet therapy.

Where a variety of agents were used, adverse effects were tabulated and assessed with descriptive techniques, as they were likely to

differ for the various agents. Where possible, the risk difference with 95% CI was calculated for each adverse effect.

Sensitivity analysis

We performed sensitivity analyses to explore the influence of the following factors on effect size.

- Repeating the analysis excluding unpublished studies
- Repeating the analysis taking account of risk of bias, as specified
- Repeating the analysis excluding any very long or large studies to establish how much they dominate the results
- Repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), and country.

'Summary of findings' tables

We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes ([Schünemann 2011a](#)). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach ([GRADE 2008](#)). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within-trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias ([Schünemann 2011b](#)). We presented the following outcomes in the 'Summary of findings' tables.

- All strokes and systemic embolic events
- Major bleeding
- Ischaemic stroke
- Haemorrhagic stroke
- MI
- Minor bleeding
- GI bleeding
- Intracranial haemorrhage
- All-cause mortality
- Vascular death

RESULTS

Description of studies

For detailed descriptions of the studies covered in this review, please see the following tables: [Characteristics of included studies](#); [Characteristics of excluded studies](#); [Characteristics of ongoing studies](#).

Results of the search

After searching the Specialised Register, contacting pharmaceutical companies, and an additional web search, we identified 177 records. After full-text review, five studies (172 records) were included ([ARISTOTLE Study 2010](#); [ENGAGE AF-TIMI 48 Study 2013](#); [J-ROCKET AF Study 2012](#); [RE-LY Study 2009](#); [ROCKET AF Study 2010](#)) and four studies (four records) were excluded ([Caluwé 2016](#);

Eriksson 2003a; Koretsune 2015; Murray 2004). One ongoing study

was identified (X-NOAC Study 2015) and will be included in a future update of this review (Figure 1).

Figure 1. Study flow diagram.

Included studies

We identified a total of 172 records representing five large studies (ARISTOTLE Study 2010; ENGAGE AF-TIMI 48 Study 2013; J-ROCKET AF Study 2012; RE-LY Study 2009; ROCKET AF Study 2010). We sent enquiry requests to the relevant pharmaceutical companies about how they dealt with missing data (the ITT analysis or modified ITT analysis). All companies responded but only one provided additional unpublished information (ARISTOTLE Study 2010).

These five studies enrolled 12,545 G3 and G4 participants. The participants had non-valvular AF and moderate kidney impairment. All five studies used the Cockcroft-Gault equation to define CrCl as a marker of kidney function. ARISTOTLE Study 2010 defined moderate kidney impairment as CrCl of 25 to 50 mL/min, while the other studies defined it as CrCl of 30 to 50 mL/min. Although participants with severe kidney impairment were exclusionary in ENGAGE AF-TIMI 48 Study 2013, a few participants with CrCl < 30 mL/min were randomised and analysed as having moderate kidney impairment.

- ARISTOTLE Study 2010 included 2747 participants (91.1%) with CKD stage G3 and 270 participants (8.9%) with CKD stage G4
- ENGAGE AF-TIMI 48 Study 2013 included 2620 participants (95.6%) with CKD stage G3 and 120 participants (4.4%) with CKD stage G4
- J-ROCKET AF Study 2012 included 284 participants with CKD stage G3
- RE-LY Study 2009 included 3554 participants with CKD stage G3
- ROCKET AF Study 2010 included 2950 participants with CKD stage G3.

Therefore, the large majority of participants included in this review were CKD stage G3 rather than stage G4 (CKD stage G3: 12,155 participants; stage G4: 390 participants).

Of 172 records, ARISTOTLE Study 2010 had 43 records, ENGAGE AF-TIMI 48 Study 2013 had 27 records, J-ROCKET AF Study 2012 had 15 records, RE-LY Study 2009 had 25 records, and ROCKET AF Study 2010 had 62 records. They included original studies and various sub studies such as different research questions, different population focused on specific conditions (e.g. elderly patients, patients with high CHADS₂ score), and conference proceedings.

We used a subset of data from these five studies, which enrolled primarily AF patients with normal kidney function. The number of patients with CKD in each study was:

- ARISTOTLE Study 2010: 3,017/18,122 (17%)
- ENGAGE AF-TIMI 48 Study 2013: 2,740/14,071 (19.5%)
- J-ROCKET AF Study 2012: 284/1,278 (22.2%)
- RE-LY Study 2009: 3,554/17,951 (19.8%)
- ROCKET AF Study 2010: 2,950/14,264 (20.7%).

The extracted participants from each study were of an acceptable sample size. We determined that the patients with CKD represented a predefined subgroup in each of the original studies, because the balance of the allocated groups had been maintained.

All five studies were RCTs. We summarized the baseline characteristics of four studies that estimated kidney function by the Cockcroft-Gault equation (ARISTOTLE Study 2010; ENGAGE AF-TIMI 48 Study 2013; J-ROCKET AF Study 2012; ROCKET AF Study 2010). RE-LY Study 2009 estimated kidney function by CKD-EPI and while the characteristics of these patients were not likely to differ from the other four studies, the results of this study were excluded from the summary of the baseline characteristics.

Mean and median age of participants ranged between 78 and 79 years, and 53.5 % were female. Previous stroke history was 35.6%, mean CHADS₂ score ranged between 2.6 and 3.7, prior vitamin K use was 56.1%, and prevalence of aspirin use was 33.6%.

Patients excluded from the included studies had: reversible AF or AF due to heart valve disorder; experienced a stroke in the past seven days; a condition associated with an increased risk of bleeding; were contraindicated for warfarin treatment; severe anaemia; received an investigational drug or medical device within 30 days before the planned clinical trial; active liver disease; severe comorbidity and whose life expectancy fell within the planned study period; were pregnant; and were unfit or unwilling to comply with the study-related procedures, such as subjects with alcohol dependence or those who refused to supply written informed consent. All studies allowed participants to use concomitant antiplatelet agents containing less than 100 mg of acetylsalicylic acid and thienopyridine, but this was restricted to a single use.

The included studies compared warfarin against the following DOAC: apixaban 2.5 or 5.0 mg (ARISTOTLE Study 2010), dabigatran 110 or 150 mg (RE-LY Study 2009), edoxaban 30 mg (ENGAGE AF-TIMI 48 Study 2013), rivaroxaban 10 mg (J-ROCKET AF Study 2012) or 15 mg (ROCKET AF Study 2010). Apixaban and dabigatran are usually administered twice a day while edoxaban and rivaroxaban were administered once daily. All studies compared DOAC with dose-adjusted warfarin using INR. The target INR for four studies,

excluding J-ROCKET AF Study 2012, was between 2.0 and 3.0 among all participants. In J-ROCKET AF Study 2012, the target INR in participants younger than 70 years was between 2.0 and 3.0, while that in those aged 70 years and older was between 1.6 and 2.5.

All five studies presented data on all composite outcomes of stroke and systematic thromboembolism as the primary efficacy outcome, with major bleeding events as the primary safety outcome. The median follow-up period ranged from 1.8 to 2.8 years.

Excluded studies

Four studies were excluded. Three studies were pharmacokinetic/pharmacodynamic studies of ximelagatran and metagatran (Eriksson 2003a), edoxaban (Koretsune 2015), and argatroban (Murray 2004), and one study compared rivaroxaban plus vitamin K2 versus vitamin K antagonist (Caluwé 2016).

Risk of bias in included studies

Figure 2 and Figure 3 summarize our assessment of risk of bias for the five included studies. Two authors independently assessed the included studies for each checklist item as having high, low, or unclear risk of bias.

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
ARISTOTLE Study 2010							
ENGAGE AF-TIMI 48 Study 2013							
J-ROCKET AF Study 2012							
RE-LY Study 2009							
ROCKET AF Study 2010							

Allocation

Four studies used a central, interactive, automated response system for allocation concealment ([ARISTOTLE Study 2010](#); [ENGAGE AF-TIMI 48 Study 2013](#); [RE-LY Study 2009](#); [ROCKET AF Study 2010](#)), while [J-ROCKET AF Study 2012](#) did not specify randomisation

or concealment methods. Therefore, we assessed the four studies to have a low risk of bias and [J-ROCKET AF Study 2012](#) to have unclear risk of bias. We used subgroup analysis results from each large study but determined that the balance of the allocated groups

had been maintained because the extracted participants from each study were of an acceptable sample size.

Blinding

Four studies had adequate double-blinding procedures (ARISTOTLE Study 2010; ENGAGE AF-TIMI 48 Study 2013; J-ROCKET AF Study 2012; ROCKET AF Study 2010). Further, independent, centralized clinical end-point committees who were blind to treatment assessed outcomes based on agreed-upon definitions. RE-LY Study 2009 had incomplete blinding, as while dabigatran was administered in a blinded fashion, warfarin was administered in an open-label fashion, and INR was adjusted at least monthly. This incomplete blinding may have led to performance bias. However, we considered that any risk of performance bias would be reduced by a predetermined equal interval of follow-up. Further, we assessed the risk of detection bias to be low because the outcomes were objective measures and outcome assessors were blinded.

Incomplete outcome data

For the primary efficacy outcome of all strokes and systematic thromboembolic events, two studies (ARISTOTLE Study 2010; RE-LY Study 2009) reported results from ITT analyses; ENGAGE AF-TIMI 48 Study 2013 reported results based on both ITT and modified ITT analyses; ROCKET AF Study 2010 reported results based on ITT, modified ITT, and PP analyses; and J-ROCKET AF Study 2012 reported results from modified ITT and PP analyses. For the primary safety outcome of major bleeding events, only RE-LY Study 2009 reported results from ITT analyses, while the other four provided results from modified ITT analyses, which included all randomised participants who had received at least one dose of the study drug during the follow-up period.

Selective reporting

We found no evidence of selective reporting bias in any of the five studies, and all predefined primary efficacy and safety outcomes in the protocols were reported in the published manuscripts.

Other potential sources of bias

All of the studies examined were sponsored by pharmaceutical companies.

Effects of interventions

See: [Summary of findings for the main comparison Direct oral anticoagulants \(DOAC\) versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease \(CKD\)](#)

See: [Summary of findings for the main comparison](#) for the main comparisons.

In the original protocol, we aimed to distinguish two primary efficacy outcomes: all strokes and systemic embolic events. However, all included studies reported composite outcomes of all strokes, including both ischaemic and haemorrhagic stroke and systemic embolic events; therefore we examined them as one composite outcome.

For both primary and secondary efficacy outcomes, including all strokes and systemic embolic events, MI, and all-cause mortality, we included the results that used the conventional ITT analyses for the four studies (ARISTOTLE Study 2010; ENGAGE AF-TIMI 48 Study

2013; RE-LY Study 2009; ROCKET AF Study 2010) and the results that used the modified ITT analyses for one study (J-ROCKET AF Study 2012). Vascular death was not reported in any of the included studies.

For primary and secondary safety outcomes, including major bleeding, minor bleeding, GI bleeding, and intracranial haemorrhage, we included the results that used modified ITT analyses for four studies (ARISTOTLE Study 2010; ENGAGE AF-TIMI 48 Study 2013; J-ROCKET AF Study 2012; ROCKET AF Study 2010) and the result that used the conventional ITT analyses for one study (RE-LY Study 2009).

Primary outcomes

All strokes and systemic embolic events

A total of 12,545 participants from all five studies were included in this analysis. We used the random-effects model to assess the association between anticoagulants and the primary efficacy outcome. DOAC probably reduced the incidence of composite outcomes in comparison with warfarin (Analysis 1.1 (5 studies, 12,545 participants): RR 0.81, 95% CI 0.65 to 1.00; moderate certainty evidence). There was no heterogeneity ($I^2 = 0\%$). We assessed the quality of evidence for the primary efficacy outcome to be moderate by GRADE because of concerns with imprecision. In addition, four studies (ARISTOTLE Study 2010; ENGAGE AF-TIMI 48 Study 2013; J-ROCKET AF Study 2012; ROCKET AF Study 2010) reported the RR of ischaemic stroke or haemorrhagic stroke. DOAC probably made little difference to the incidence of ischaemic stroke in comparison with warfarin (Analysis 1.2 (4 studies, 8,991 participants): RR 1.01, 95% CI 0.75 to 1.36; moderate certainty evidence). There was no heterogeneity ($I^2 = 0\%$). In contrast, DOAC probably reduced the incidence of haemorrhagic stroke in comparison with warfarin (Analysis 1.3 (4 studies, 8,991 participants): RR 0.52, 95% CI 0.28 to 0.97; moderate certainty evidence). There was no heterogeneity ($I^2 = 0\%$). We assessed the quality of evidence concerning both ischaemic and haemorrhagic strokes to be moderate because of concerns with imprecision.

Major bleeding

A total of 12,521 participants from all five studies reported major bleeding events, defined as a reduction in at least 20 g/L of haemoglobin, transfusion of at least two units of blood, symptomatic bleeding in a critical area or organ, or death due to major bleeding, according to the ISTH criteria. DOAC might slightly reduce the incidence of major bleeding events in comparison with warfarin (Analysis 1.4 (5 studies, 12,521 participants): RR 0.79, 95% CI 0.59 to 1.04; low certainty evidence). There was medium heterogeneity ($I^2 = 63\%$). We assessed the quality of evidence for the primary safety outcome to be low by GRADE because of concerns with inconsistency and imprecision.

Secondary outcomes

Myocardial infarction

ENGAGE AF-TIMI 48 Study 2013 reported no difference in the incidence of MI between DOAC compared to warfarin (Analysis 1.5 (1 study, 2,740 participants): RR 0.92, 95% CI 0.45 to 1.90). Although the other four studies (ARISTOTLE Study 2010; J-ROCKET AF Study 2012; RE-LY Study 2009; ROCKET AF Study 2010) indicated that they would assess the incidence of MI in their protocol, ARISTOTLE Study 2010 and J-ROCKET AF Study 2012 did not report on the results,

while [RE-LY Study 2009](#) and [ROCKET AF Study 2010](#) reported the composite outcomes for stroke, systemic embolic events, MI and others, but not separately for these items.

Minor bleeding

Two studies ([ENGAGE AF-TIMI 48 Study 2013](#); [J-ROCKET AF Study 2012](#)) reported that DOAC might make little difference to minor bleeding events in comparison with warfarin ([Analysis 1.6](#) (2 studies, 3,012 participants): RR 0.97, 95% CI 0.58 to 1.61; low certainty evidence). There was substantial heterogeneity ($I^2 = 70\%$). We assessed the quality of evidence to be low because of concerns with inconsistency and imprecision. No data was available for the other three studies ([ARISTOTLE Study 2010](#); [RE-LY Study 2009](#); [ROCKET AF Study 2010](#)).

Gastrointestinal bleeding

Two studies ([ENGAGE AF-TIMI 48 Study 2013](#); [ROCKET AF Study 2010](#)) reported that DOAC probably led to slightly more GI bleeding events in comparison with warfarin ([Analysis 1.7](#) (2 studies, 5,678 participants): RR 1.40, 95% CI 0.97 to 2.01; moderate certainty evidence). There was no heterogeneity ($I^2 = 0\%$). We assessed the quality of evidence to be moderate because of concerns with imprecision. No data was available for the other three studies ([ARISTOTLE Study 2010](#); [J-ROCKET AF Study 2012](#); [RE-LY Study 2009](#)).

Intracranial haemorrhage

All five studies reported that DOAC probably reduced intracranial haemorrhage events in comparison with warfarin ([Analysis 1.8](#) (5 studies, 12,521 participants): RR 0.43, 95% CI 0.27 to 0.69; moderate certainty evidence). There was low heterogeneity ($I^2 = 25\%$). We assessed the quality of evidence to be moderate because of concerns with imprecision.

All-cause mortality

Four studies ([ARISTOTLE Study 2010](#); [ENGAGE AF-TIMI 48 Study 2013](#); [J-ROCKET AF Study 2012](#); [RE-LY Study 2009](#)) reported that DOAC probably make little difference to all-cause mortality in comparison with warfarin ([Analysis 1.9](#) (4 studies, 9,595 participants): RR 0.91, 95% CI 0.78 to 1.05; moderate certainty evidence). There was no heterogeneity ($I^2 = 0\%$). We assessed the quality of evidence to be moderate because of concerns with imprecision. Although [ROCKET AF Study 2010](#) also indicated the assessment of all-cause mortality in their protocol, the results were not reported.

Vascular death

We could not obtain the results for vascular death from any of the included studies.

Subgroup analyses

We conducted several pre-defined subgroup analyses for both the primary efficacy outcome and primary safety outcome to explore the heterogeneity of treatment effects.

CKD stages

[ARISTOTLE Study 2010](#) and [ENGAGE AF-TIMI 48 Study 2013](#) included several participants with CrCl < 30 mL/min. In the original articles, these participants were analysed as having moderate kidney

impairment. However, an FDA report for [ENGAGE AF-TIMI 48 Study 2013](#) and a report from the pharmaceutical company for [ARISTOTLE Study 2010](#) categorised the data differently, as CKD stage 3 (CrCl 30 to 50 mL/min) and CKD stage 4 (CrCl 15 to 30 mL/min), respectively. Therefore, we re-analysed the primary outcomes according to CKD stage, categorising 12,155 participants as CKD stage G3 and 390 participants as stage G4.

DOAC probably slightly reduced the composite efficacy outcomes of all strokes and systemic embolic events in comparison with warfarin for participants with CKD stage 3 ([Analysis 2.1](#) (5 studies, 12,155 participants): RR 0.82, 95% CI 0.66 to 1.02; moderate certainty evidence). There was no heterogeneity ($I^2 = 0\%$). Likewise, DOAC might slightly reduce the composite efficacy outcomes in comparison with warfarin for participants with CKD stage G4 ([Analysis 3.1](#) (2 studies, 390 participants): RR 0.68, 95% CI 0.23 to 2.00; low certainty evidence). There was no heterogeneity ($I^2 = 0\%$). These results were consistent with the overall results.

DOAC probably slightly reduced major bleeding events in comparison with warfarin for participants with CKD stage G3 ([Analysis 2.2](#) (5 studies, 12,132 participants): RR 0.80, 95% CI 0.62 to 1.03; moderate certainty evidence). There was moderate heterogeneity ($I^2 = 53\%$). Only one study ([ARISTOTLE Study 2010](#)) of 268 participants with CKD stage G4 reported that DOAC might improve major bleeding events in comparison with warfarin ([Analysis 3.2](#) (1 studies, 268 participants): RR 0.30, 95% CI 0.11 to 0.80).

Other baseline characteristics

No data were available for subgroup analyses of other participant characteristics such as age, history of stroke and risk factors of baseline stroke (CHADS₂ score). Additional assessments are required once more information is published.

How to prescribe anticoagulants

Dose and duration of therapy per day

Participants in [RE-LY Study 2009](#) were randomly assigned to receive either 110 mg or 150 mg of dabigatran twice a day. Participants in [ARISTOTLE Study 2010](#) were prescribed either 2.5 mg or 5 mg of apixaban twice a day, with dosage determined according to whether participants satisfied two or more of the following criteria: (i) age ≥ 80 years; (ii) body weight ≤ 60 kg; or (iii) SCr ≥ 1.5 mg/dL (133 μmol/L). Participants in the other three studies were administered single doses ([ENGAGE AF-TIMI 48 Study 2013](#): 30 mg edoxaban once a day; [ROCKET AF Study 2010](#): 15 mg rivaroxaban once a day; [J-ROCKET AF Study 2012](#): 10 mg rivaroxaban once a day).

We conducted subgroup analyses to assess the different dosages of DOAC. In [RE-LY Study 2009](#), the patients were randomised in a 1:1:1 fashion, 110 mg of dabigatran, 150 mg of dabigatran or dose-adjusted warfarin, and the results of analyses were separately shown for dabigatran 110 mg versus warfarin and for dabigatran 150 mg versus warfarin. However, we could not obtain the results for different dosages of apixaban ([ARISTOTLE Study 2010](#)). We entered two comparisons of dabigatran (dabigatran 110 mg versus warfarin, and dabigatran 150 mg versus warfarin) into the meta-analysis. Participants on DOAC probably reduced the composite primary efficacy outcomes of all strokes and systemic embolic events in comparison with warfarin ([Analysis 4.1](#) (5 studies, 12,545 participants): RR 0.81, 95% CI 0.65 to 1.00; moderate certainty

evidence). There was no heterogeneity ($I^2 = 0\%$). Likewise, DOAC probably made little difference to all-cause mortality as the secondary efficacy outcome in comparison with warfarin ([Analysis 4.3](#) (4 studies, 9,595 participants): RR 0.91, 95% CI 0.78 to 1.05; moderate certainty evidence). There was no heterogeneity ($I^2 = 0\%$). Further, DOAC might slightly reduce the incidence of major bleeding in comparison with warfarin ([Analysis 4.2](#) (5 studies, 12,521 participants): RR 0.81, 95% CI 0.63 to 1.03; low certainty evidence). There was moderate heterogeneity ($I^2 = 54\%$). These results were mostly consistent with the original results.

No data were available for the comparison of the duration of each therapy.

Subtype of DOAC

Rivaroxaban was studied in two studies ([ROCKET AF Study 2010](#); [J-ROCKET AF Study 2012](#)). However, the sample size of [J-ROCKET AF Study 2012](#) was smaller than [ROCKET AF Study 2010](#), and the prescribed doses were different between the studies. Therefore, it was difficult to perform subtype analysis. All other drugs were examined by a single study respectively, so we could not assess differences in DOAC subtypes.

Concomitant use of antiplatelet therapy

All studies allowed the use of less than 100 mg or 165 mg of aspirin, and all but one study ([ENGAGE AF-TIMI 48 Study 2013](#)) permitted the use of antiplatelet agents such as thienopyridine. However, no data were available for subgroup analysis.

Adverse events

Several adverse events were assessed for rivaroxaban ([ROCKET AF Study 2010](#); [J-ROCKET AF Study 2012](#)). Rivaroxaban might make little difference to any adverse effects in comparison with warfarin (see results; [Analysis 5](#)).

Sensitivity analysis

We planned several pre-defined sensitivity analyses for both the primary efficacy outcome and primary safety outcome to explore the influence on effect size.

We did not carry out the sensitivity analysis for repeating the analysis excluding unpublished studies, because our study did not include unpublished studies. We did not carry out the sensitivity analysis for repeating the analysis taking into account risk of bias, because we considered the risk of bias to be low. We did not carry out the sensitivity analysis for repeating the analysis excluding any very long or large studies to establish how much they dominate the results, because the sample size of [J-ROCKET AF Study 2012](#) was small, and other studies had similar weight. We also did not the sensitivity analysis for repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), and country. The criteria for kidney impairment and warfarin dosage were previously described and similar, and other criteria were similar. All included publications were written in English. All studies were supported by pharmaceutical research companies. Various western or Asian countries were involved in all studies except for [J-ROCKET AF Study 2012](#), which targeted Japanese participants only.

Analysis using fixed effects model

We performed sensitivity analyses using the fixed-effect model. DOAC probably slightly reduced the incidence of composite outcomes in comparison with warfarin ([Analysis 6.1](#) (5 studies, 12,545 participants): RR 0.81, 95% CI 0.65 to 1.01; moderate certainty evidence). There was no heterogeneity ($I^2 = 0\%$). Further, DOAC probably reduced the incidence of major bleeding in comparison with warfarin ([Analysis 6.2](#) (5 studies, 12,521 participants): RR 0.79, 95% CI 0.67 to 0.92; low certainty evidence). There was medium heterogeneity ($I^2 = 63\%$). The results obtained using the fixed-effects model were mostly consistent with those obtained using the random-effects model even though the point estimates and 95% CIs were slightly different.

DISCUSSION

Summary of main results

We analysed 12,545 AF patients with moderate to severe kidney impairment in five RCTs that examined the efficacy and safety of four DOAC: apixaban, dabigatran, edoxaban, and rivaroxaban.

Included studies directly compared the association between DOAC and dose-adjusted warfarin for the composite outcomes of all strokes and systemic embolic events as the primary efficacy outcome, and major bleeding as the primary safety outcome. AF patients with CKD on DOAC probably reduced the incidence of all strokes and systemic embolic events in comparison with warfarin. Further, participants on DOAC might slightly reduce the incidence of major bleeding events.

This was the subset of data from five large studies, which enrolled primarily AF patients regardless of kidney function. The incidence of all strokes and systemic embolic events among patients with CKD was probably slightly consistent with among all participants from the original studies ([Bruins Slot 2013](#)). Further, the point estimates for the incidence of major bleeding among participants with CKD were lower than those among patients without kidney impairment, although 95% CI was larger because of the smaller sample size.

The results of subgroup analyses according to CKD stage G3 and G4 were mostly consistent with the overall results. The only point of difference was that CKD stage G4 ([ARISTOTLE Study 2010](#)) DOAC might reduce major bleeding events in comparison with warfarin, but the number of participants categorised into CKD stage G4 was small, so we could not assess the association with sufficient power.

These findings indicate that DOAC are more or similarly effective and similarly safe for AF patients with CKD as dose-adjusted warfarin, at least in stage 3 CKD. Physicians can therefore feel more confident in prescribing DOAC to AF patients with CKD without the burden of regular monitoring that is necessary for warfarin.

Overall completeness and applicability of evidence

Currently, major regulatory agencies ([EMA 2014](#); [FDA 2014](#); [Health Canada 2017](#)) have approved DOAC for use by AF patients with CKD stage G3 or G4, but evidence supporting their use is limited ([Reinecke 2013](#)).

We systematically reviewed the studies that re-analysed the subgroups; that is, participants with kidney impairment, of the five large RCTs targeting AF participants. The sample size of each

subgroup study was large and the balance and comparability of randomised baseline characteristics was retained in these subgroups.

All participants in the intervention and control groups had non-valvular AF and CKD, and other baseline characteristics were similar across the studies. Warfarin was controlled within the range of the INR of 2.0 to 3.0 for four studies, excluding [J-ROCKET AF Study 2012](#), and the conditions for comparisons were consistent across studies. In [J-ROCKET AF Study 2012](#), the target INR range was 2.0 to 3.0 for participants younger than 70 years and 1.6 to 2.5 for those aged 70 years and older.

Each study also included participants from western and Asian countries, indicating that the data were higher generalizable.

This systematic review had several limitations. First, [ARISTOTLE Study 2010](#) and [ENGAGE AF-TIMI 48 Study 2013](#) included participants with severe kidney impairment (CrCl < 30 mL/min). However, as shown in the subgroup analyses, our results chiefly apply to CKD stage G3 patients, so further studies are required to determine the efficacy and safety of DOAC on patients with CKD stage G4. Additionally, we could not examine the effects on CKD stage G5 patients. Although recent meta-analyses showed that warfarin may not be beneficial for patients with end-stage kidney disease, the effect of DOAC on these patients is unclear ([Dahal 2016](#); [Liu 2015](#)). Future reviews should assess participants with more advanced CKD stages. Second, kidney function can be measured using several parameters and equations, such as CrCl, estimated by Cockcroft-Gault equation; and eGFR, estimated by the Modification of Diet in Renal Disease (MDRD) equation or CKD-EPI. GFR as estimated by MDRD or CKD-EPI may be more precise than CrCl ([Levey 2006](#); [Levey 2009](#)). However, we could not estimate GFR using MDRD or CKD-EPI because the number of participants within each group were not indicated. We used CrCl estimated by the Cockcroft-Gault equation because it is widely used and all RCTs included in this review estimated kidney function using this method. Third, we could not perform some subgroup or sensitivity analyses due to lack of available data. In particular, it is important to assess subtypes or different dosages of DOAC to explore possible sources of heterogeneity. Such analyses should be conducted once more RCT results have been obtained, and the analyses in this study repeated after the publication of more data.

Quality of the evidence

Only [RE-LY Study 2009](#) was conducted in single blinded fashion; however, since the outcome assessors were blinded, we concluded that this analysis method did not have adverse effects on the results. We assessed the risk of bias for both the primary efficacy and primary safety outcomes to be low. However, this study did not report important secondary outcomes such as MI and all-cause mortality even though they were predefined in the protocol; therefore, outcome reporting bias was suspected.

We could not assess differences in the types or dosages of DOAC sufficiently. We could not obtain the results for different dosages of apixaban. It is possible that higher doses caused more serious bleeding than lower doses, but this information is hidden by combining the dosages.

To assess publication of incomplete outcome data, which is related to attrition bias, we basically adopted the ITT principle for the

primary efficacy outcome and the modified ITT principle for the primary safety outcome. The ITT principle for the efficacy outcomes maintains the balance of random allocation and is generally conservative by accepting the results of noncompliance and dropouts. In contrast, safety outcomes should not be diluted by noncompliance or dropouts, making the modified ITT principle more appropriate. [J-ROCKET AF Study 2012](#) used modified ITT for efficacy outcomes and [RE-LY Study 2009](#) used conventional ITT for safety outcomes. We expected that the relative measure (RR) was probably similar in conventional ITT and modified ITT analyses because this review adapted an active comparator. Therefore, we considered that adherence was likely to be similar in both groups and not to be related to the efficacy and the safety.

Funding biases can also affect the results of studies. Since all of the included studies followed the pre-defined protocol, we considered that the impact, if any, was small.

Using the GRADE system, we assessed the primary efficacy outcome to be of moderate quality due to concerns with imprecision and the primary safety outcome to be of low certainty due to concerns with inconsistency and imprecision. For the secondary outcomes, we assessed the results for minor bleeding to be of low certainty due to concerns with inconsistency and imprecision, GI bleeding, intracranial haemorrhage, and all-cause mortality to be of moderate certainty due to concerns with imprecision, respectively.

Potential biases in the review process

We performed a comprehensive search using several different databases but we cannot rule out the possibility that we may have missed several smaller studies. Further, we contacted the sponsors and performed web searches to collect data that we could not obtain from the Cochrane Kidney and Transplant Specialised Register, but there may still be a possibility that we missed some data.

Agreements and disagreements with other studies or reviews

A previous systematic review reported that DOAC were more effective than warfarin in preventing stroke and systemic embolism among AF patients regardless of kidney function, but the evidence among patients with kidney impairment were not established. Since CKD patients have an increased risk of stroke compared to the general population, preventive strategies for stroke are necessary for these patients ([Lau 2016](#); [Marinigh 2011](#); [Masson 2015](#)). However, clinicians hesitate to prescribe anticoagulants to CKD patients due to concerns about bleeding risks ([Lau 2016](#)). For example, dabigatran is predominantly excreted from the kidneys ([Stangier 2008](#)), so there is a risk that blood concentrations of the drug may rise.

The included original RCTs were all designed as non-inferiority studies and the data from a smaller group of participants in this review showed consistent results. Moreover, the point estimates among CKD participants were lower than among those without kidney impairment; variability (by 95% CI) was larger because of the smaller sample size.

AUTHORS' CONCLUSIONS

Implications for practice

DOAC are as likely as warfarin to prevent all strokes and systemic embolic events without increasing risk of major bleeding events among AF patients with kidney impairment. These findings should encourage physicians to prescribe DOAC to AF patients with CKD. Additionally, prescription of DOAC may improve quality of life because, unlike warfarin, they do not require regular monitoring or restrictions on foods or other drugs.

Implications for research

Several concerns remain and future studies should address the following points.

1. This study could not assess the effectiveness or safety of DOAC among patients with severe kidney dysfunction, such as those with CrCl < 30 mL/min, especially haemodialysis patients; it is important to establish the recommendations for these patients.

2. Other subgroup analyses using baseline characteristics such as age, history of previous stroke, and stroke risk factors (assessed by CHADS₂ score) should be conducted. Further, future studies should assess the impact of concomitant use of antiplatelet agents and DOAC.
3. We could not sufficiently assess the effect of DOAC on important secondary outcomes such as MI, minor bleeding and vascular death because of lack of available data. Therefore, these analyses should be repeated after the publication of more data.
4. The included studies had a maximum follow up period of 2.8 years. Future studies should assess the long-term effectiveness and safety of DOAC use.
5. Future studies should compare subtypes dosages of DOAC so as to provide clinicians with the comparative effectiveness of available alternatives.

ACKNOWLEDGEMENTS

We would like to thank the referees for their advice and feedback during the preparation of this manuscript.

REFERENCES

References to studies included in this review

ARISTOTLE Study 2010 {published data only}

Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. *European Heart Journal* 2013;**34**(31):2464-71. [MEDLINE: 23594592]

Alexander JH, Levy E, Lawrence J, Hanna M, Wacławski AP, Wang J, et al. Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. *American Heart Journal* 2013;**166**(3):559-65. [MEDLINE: 24016507]

Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. *European Heart Journal* 2014;**35**(4):224-32. [MEDLINE: 24144788]

Avezum A, Bahit CM, Hermosillo AG, Zanetti FL, Isaza-Restrepo D, Juarez-Garcia A. Apixaban versus warfarin in patients with atrial fibrillation: patient characteristics of the Latin America cohort from a multinational clinical trial [abstract]. *Stroke* 2015;**46**(Suppl 1):AWP147. [CENTRAL: CN-01067615]

Avezum A, Lopes RD, Schulte PJ, Lanás F, Gersh BJ, Hanna M, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: Findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *Circulation* 2015;**132**(8):624-32. [MEDLINE: 26106009]

Avezum A, Lopes RD, Schulte PJ, Lanás F, Hanna M, Pais P. Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE trial [abstract]. *European Heart Journal* 2013;**34**(Suppl 1):809. [CENTRAL: CN-00886584]

Bahit MC, Lopes RD, Hohnloser SH, Wojdyla D, Alexander JH, Lewis BS, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial [abstract no: 13026]. *Circulation* 2012;**126**(21 Suppl 1). [EMBASE: 70956622]

Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. *International Journal of Cardiology* 2013;**170**(2):215-20. [MEDLINE: 24192334]

Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. *Journal of Thrombosis & Haemostasis* 2014;**12**(9):1401-12. [MEDLINE: 24942912]

De Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, et al. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the

Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. *American Heart Journal* 2016;**175**:175-83. [MEDLINE: 27179738]

Diener HC, Easton JD, Alings M, Bahit C, Goto S, Lewis BS. Apixaban compared with warfarin in patients with atrial fibrillation and prior stroke or TIA: a subgroup analysis of the ARISTOTLE trial [abstract]. *Cerebrovascular Diseases* 2012;**33**(Suppl 2):47. [CENTRAL: CN-00854732]

Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. *European Heart Journal* 2014;**35**(28):1897-906. [MEDLINE: 24513791]

Durheim MT, Cyr DD, Lopes RD, Thomas LE, Tsuang WM, Gersh BJ, et al. Chronic obstructive pulmonary disease in patients with atrial fibrillation: insights from the ARISTOTLE trial. *International Journal of Cardiology* 2016;**202**:589-94. [MEDLINE: 26447668]

Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. [Erratum appears in *Lancet Neurol.* 2012 Dec;11(12):1021]. *Lancet Neurology* 2012;**11**(6):503-11. [MEDLINE: 22572202]

Ezekowitz J, Dorian P, Granger C, Alexander J, Lopes R, Hanna M, et al. Efficacy and safety of apixaban compared to warfarin for prevention of stroke and systemic embolism in 18,201 patients with atrial fibrillation: Primary results of the ARISTOTLE trial [abstract]. *Canadian Journal of Cardiology* 2011;**27**(5 Suppl 1):S334. [EMBASE: 70608602]

Flaker G, Lopes R, Al-Khatib S, Hermosillo A, Thomas L, Zhu J, et al. Apixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation: results from the ARISTOTLE Trial [abstract no: 4048]. *European Heart Journal* 2012;**33**(Suppl 1):686. [EMBASE: 70884980]

Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). *Journal of the American College of Cardiology* 2014;**63**(11):1082-7. [MEDLINE: 24211508]

Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Journal of the American College of Cardiology* 2014;**64**(15):1541-50. [MEDLINE: 25301455]

Flaker GC, Hohnloser S, Wojdyla D, Hylek E, Garcia D, Sullivan R, et al. Apixaban is efficacious and safe in patients with atrial fibrillation using concomitant amiodarone: an analysis from the ARISTOTLE trial [abstract]. *Journal of the American College of Cardiology* 2013;**61**(10 Suppl 1):E317. [EMBASE: 71019680]

Garcia DA, Alexander JH, Lopes RD, Thomas L, Yang H, Ansell J, et al. Apixaban versus warfarin in patients with atrial fibrillation in relation to prior warfarin use: Insights from the ARISTOTLE trial [abstract no: 14771]. *Circulation* 2012;**126**(21 Suppl 1). [EMBASE: 70958949]

Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. *American Heart Journal* 2013;**166**(3):549-58. [MEDLINE: 24016506]

Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, Aylward P, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *American Heart Journal* 2014;**168**(3):303-9. [MEDLINE: 25173541]

Granger CB, Alexander JH, Hanna M, Wang J, Mohan P, Lawrence J, et al. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial [abstract no: 4045]. *European Heart Journal* 2012;**33**(Suppl 1):685-6. [EMBASE: 70884977]

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine* 2011;**365**(11):981-92. [MEDLINE: 21870978]

Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. *European Heart Journal* 2014;**35**(28):1864-72. [MEDLINE: 24561548]

Held C, Hylek EB, Alexander JH, Hanna M, Lopes RD, Wojdyla D, et al. Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial [abstract]. *European Heart Journal* 2013;**34**:99. [EMBASE: 71257890]

Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. *European Heart Journal* 2015;**36**(20):1264-72. [MEDLINE: 25499871]

Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. *Circulation* 2014;**129**(6):625-34. [MEDLINE: 24226808]

Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, et al. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. *Clinical Chemistry* 2015;**61**(2):368-78. [MEDLINE: 25451868]

Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. *Journal of the American College of Cardiology* 2014;**63**(1):52-61. [MEDLINE: 24055845]

Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). *Journal of the American College of Cardiology* 2013;**61**(22):2274-84. [MEDLINE: 23563134]

* Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. *European Heart Journal* 2012;**33**(22):2821-30. [MEDLINE: 22933567]

Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.[Erratum appears in Lancet. 2013 Jan 19;381(9862):204]. *Lancet* 2012;**380**(9855):1749-58. [MEDLINE: 23036896]

Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.[Erratum appears in Am Heart J. 2010 Jun;159(6):1162]. *American Heart Journal* 2010;**159**(3):331-9. [MEDLINE: 20211292]

McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Circulation: Heart Failure* 2013;**6**(3):451-60. [MEDLINE: 23575255]

Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. *Circulation Journal* 2011;**75**(8):1852-9. [MEDLINE: 21670542]

Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, et al. Blood pressure control and risk of stroke or systemic embolism inpatients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. *Journal of the American Heart Association* 2015;**4**(12):e002015. [MEDLINE: 26627878]

Rordorf R, de Ferrari GM, Wojdyla D, De Caterina R, Thomas L, Granger CB, et al. Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure: insights from the ARISTOTLE trial [abstract]. *European Heart Journal* 2015;**36**:1068. [EMBASE: 72022734]

Sandhu RK, Ezekowitz J, Andersson U, Alexander J, Granger C, Halvorsen S, et al. Body mass index and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial [abstract].

Journal of the American College of Cardiology 2015;**65**(10 Suppl 1):A284. [EMBASE: 71833341]

Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, et al. The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. *European Heart Journal* 2016;**37**(38):2869-78. [MEDLINE: 27071819]

Siegbahn A, Christersson C, Schollin M, Alexander JH, Horowitz J, Hylek EM, et al. Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy [abstract no: P553]. *European Heart Journal* 2012;**33**(Suppl 1):51. [EMBASE: 70882600]

Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, et al. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. *European Heart Journal* 2015;**36**(46):3268-75. [MEDLINE: 26371113]

Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. *Circulation* 2013;**127**(22):2166-76. [MEDLINE: 23640971]

ENGAGE AF-TIMI 48 Study 2013 {published data only}

* Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. *Circulation* 2016;**134**(1):24-36. [MEDLINE: 27358434]

Deepak KG, Shah A, Giugliano R, Ruff C, Antman E, Laura TG, et al. Cardiac structure and function and CHADS2 risk score in patients with atrial fibrillation: the effective anticoagulation with factor Xa next generation in afthrombolysis in myocardial infarction 48 (ENGAGE AF - TIMI 48) echocardiographic study [abstract]. *Journal of the American College of Cardiology* 2013;**61**(10 Suppl 1):E964. [EMBASE: 71020327]

Douketis J, Weitz J, Murphy S, Deenadayalu N, Crompton AE, Mercuri M, et al. Perioperative adverse outcomes in patients with atrial fibrillation taking edoxaban or warfarin: analysis of the ENGAGE AF-TIMI 48 trial [abstract]. *Journal of the American College of Cardiology* 2015;**65**(10 Suppl 1):A2092. [EMBASE: 71835148]

Eisen A, Giugliano RP, Ruff CT, Nordio F, Gogia HS, Awasty VR, et al. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: an analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. *American Heart Journal* 2016;**172**:144-51. [MEDLINE: 26856226]

Geller BJ, Giugliano RP, Braunwald E, Murphy SA, Hanyok JJ, Jin J, et al. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With

Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. *American Heart Journal* 2015;**170**(4):669-74. [MEDLINE: 26386790]

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Grip LT, Betcher JM, et al. ENGAGE AF-TIMI 48 primary results [abstract]. *Circulation* 2013;**128**(24):2711-2. [EMBASE: 71281640]

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine* 2013;**369**(22):2093-104. [MEDLINE: 24251359]

Giugliano RP, Ruff CT, Rost NS, Silverman S, Wiviott SD, Lowe C, et al. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. *Stroke* 2014;**45**(8):2372-8. [MEDLINE: 24947287]

Giugliano RP, Ruff CT, Wiviott SD, Murphy SA, Kappelhof JAN, Shi M, et al. Reduction in bleeding with edoxaban vs warfarin linked to lower all-cause mortality in 21,105 patients randomized in the ENGAGE AF-TIMI 48 trial [abstract]. *European Heart Journal* 2014;**35**(Suppl 1):867. [EMBASE: 71649981]

Giugliano RP, Ruff CT, Wiviott SD, Nordio F, Murphy SA, Kappelhof JA, et al. Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. *American Journal of Medicine* 2016;**129**(8):850-7, e2. [MEDLINE: 26994510]

Gupta D, Giugliano RP, Ruff CT, Claggett B, Murphy S, Antman E, et al. The prognostic significance of cardiac structure and function in atrial fibrillation: the ENGAGE AF-TIMI 48 Echocardiographic Substudy [abstract]. *European Heart Journal* 2014;**35**(Suppl 1):1117. [EMBASE: 71650934]

Gupta DK, Giugliano RP, Ruff CT, Claggett B, Murphy S, Antman E, et al. The prognostic significance of cardiac structure and function in atrial fibrillation: The ENGAGE AF-TIMI 48 echocardiographic substudy. *Journal of the American Society of Echocardiography* 2016;**29**(6):537-44. [MEDLINE: 27106009]

Gupta DK, Shah AM, Giugliano RP, Ruff CT, Antman EM, Grip LT, et al. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. *European Heart Journal* 2014;**35**(22):1457-65. [MEDLINE: 24302269]

Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial. *Journal of the American Heart Association* 2016;**5**(5):e003432. [MEDLINE: 27207971]

Krekels EH, Niebecker R, Karlsson MO, Miller R, Shimizu T, Karlsson KE, et al. Population pharmacokinetics of edoxaban in patients with non-valvular atrial fibrillation in the ENGAGE AF-TIMI 48 Study, a phase III clinical trial. *Clinical Pharmacokinetics* 2016;**55**(9):1079-90. [MEDLINE: 26951208]

Magnuson EA, Wang K, Li H, Kwong WJ, Antman EM, Ruff CT, et al. Impact of spontaneous bleeding events on health state utility in patients with atrial fibrillation: Results from

the ENGAGE AF-TIMI 48 trial [abstract no: 314]. *Circulation* 2014;**7**(Suppl 1):A314. [EMBASE: 71669975]

Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet* 2015;**385**(9984):2280-7. [MEDLINE: 25769357]

Ruff CT, Giugliano R, Braunwald E, Morrow D, Murphy S, Deenadayalu N, et al. Relationship between dose, anti-factor Xa activity, and outcomes in patients randomized to edoxaban in the ENGAGE AF-TIMI 48 trial [abstract]. *Journal of the American College of Cardiology* 2014;**63**(12 Suppl 1):A329. [EMBASE: 71406353]

Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoagulation with factor Xa next GEneration in Atrial Fibrillation- Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). *American Heart Journal* 2010;**160**(4):635-41. [MEDLINE: 20934556]

Ruff CT, Giugliano RP, Braunwald E, Mercuri M, Curt V, Betcher J, et al. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. *Journal of the American College of Cardiology* 2014;**64**(6):576-84. [MEDLINE: 25104527]

Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet* 2015;**385**(9984):2288-95. [MEDLINE: 25769361]

Ruff CT, Giugliano RP, Braunwald E, Murphy SA, Brown K, Jarolim P, et al. Cardiovascular biomarker score and clinical outcomes in patients with atrial fibrillation enrolled in the ENGAGE AF-TIMI 48 trial [abstract no: P2481]. *European Heart Journal* 2014;**35**(Suppl 1):440. [EMBASE: 71648380]

Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. *Thrombosis & Haemostasis* 2012;**107**(5):925-36. [MEDLINE: 22398655]

Shimada YJ, Yamashita T, Koretsune Y, Kimura T, Abe K, Sasaki S, et al. Effects of regional differences in Asia on efficacy and safety of edoxaban compared with warfarin: insights from the ENGAGE AF-TIMI 48 trial. *Circulation Journal* 2015;**79**(12):2560-7. [MEDLINE: 26460886]

Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel H, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. *European Heart Journal* 2015;**36**(33):2239-45. [MEDLINE: 25971288]

Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, et al. Concomitant use of single antiplatelet therapy with edoxaban

or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 Trial. *Journal of the American Heart Association* 2016;**5**(2):e002587. [MEDLINE: 26908401]

Yamashita T, Koretsune Y, Yang Y, Chen SA, Chung N, Shimada YJ, et al. Edoxaban vs. warfarin in East Asian patients with atrial fibrillation- an ENGAGE AF-TIMI 48 subanalysis. *Circulation Journal* 2016;**80**(4):860-9. [MEDLINE: 26888149]

J-ROCKET AF Study 2012 {published data only}

Safety/efficacy of rivaroxaban for prevention of stroke in Japanese atrial fibrillation patients - Sub-analysis of renal impairment in J-ROCKET AF [abstract]. *Therapeutic Research* 2012;**33**(7):957-8. [EMBASE: 365495775]

Chan MY, Lin M, Lucas J, Moseley A, Thompson JW, Cyr D, et al. Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. *Thrombosis & Haemostasis* 2012;**108**(6):1180-91. [MEDLINE: 23052711]

Delgado-Fernandez M. The J-ROCKET AF study: A matter of ethnicity or a matter of weight?. *Circulation Journal* 2013;**77**(10):2636. [EMBASE: 2013608415]

* Hori M, Kajikawa M. The J-ROCKET AF study: A matter of ethnicity or a matter of weight?. *Circulation Journal* 2013;**77**(10):2637. [MEDLINE: 23903065]

Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. J-ROCKET AF: The safety and efficacy of rivaroxaban for prevention of stroke in Japanese patients with non-valvular atrial fibrillation [abstract]. *Journal of Thrombosis and Haemostasis* 2011;**9**:20. [EMBASE: 70612436]

Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial. *Journal of Stroke & Cerebrovascular Diseases* 2014;**23**(2):379-83. [MEDLINE: 23954611]

Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. Warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age. *Circulation Journal* 2014;**78**(6):1349-56. [MEDLINE: 24705469]

Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. *Circulation Journal* 2012;**76**(9):2104-11. [MEDLINE: 22664783]

Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. *Circulation Journal* 2013;**77**(3):632-8. [MEDLINE: 23229461]

Kaneko M, Tanigawa T, Hashizume K, Kajikawa M, Tajiri M, Mueck W. Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients. *Drug Metabolism & Pharmacokinetics* 2013;**28**(4):321-31. [MEDLINE: 23337693]

Matsumoto M, Hori M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: A subgroup analysis of the J-ROCKET AF trial. *Hypertension Research - Clinical & Experimental* 2014;**37**(5):457-62. [MEDLINE: 24477179]

Tanahashi N, Hori M, Matsumoto M, Momomura SI, Uchiyama S, Goto S, et al. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: A subgroup analysis of J-ROCKET AF. *Journal of Stroke & Cerebrovascular Diseases* 2013;**22**(8):1317-25. [MEDLINE: 23352688]

Tanigawa T, Kaneko M, Hashizume K, Kajikawa M, Ueda H, Tajiri M, et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. *Drug Metabolism & Pharmacokinetics* 2013;**28**(1):59-70. [MEDLINE: 22813718]

Uchiyama S, Hori M, Matsumoto M, Tanahashi N, Momomura S, Goto S, et al. Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF. *Journal of Stroke & Cerebrovascular Diseases* 2014;**23**(5):1142-7. [MEDLINE: 24189454]

Uchiyama S, Hori M, Matsumoto M, Tanahashi N, Momomura S, Goto S, et al. Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF. *Journal of Stroke & Cerebrovascular Diseases* 2014;**23**(5):1142-7. [MEDLINE: 24189454]

RE-LY Study 2009 {published data only}

Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY Trial. *Journal of the American College of Cardiology* 2015;**65**(23):2481-93. [MEDLINE: 26065986]

Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. *Clinical Gastroenterology & Hepatology* 2013;**11**(3):246-52. [MEDLINE: 23103906]

* Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation.[Erratum appears in N Engl J Med. 2010 Nov 4;363(19):1877]. *New England Journal of Medicine* 2009;**361**(12):1139-51. [MEDLINE: 19717844]

Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. *Circulation* 2013;**127**(5):634-40. [MEDLINE: 23271794]

Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.[Erratum

appears in Lancet Neurol. 2011 Jan;10(1):27]. *Lancet Neurology* 2010;**9**(12):1157-63. [MEDLINE: 21059484]

Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. *Thrombosis & Haemostasis* 2015;**113**(3):625-32. [MEDLINE: 25472710]

Douketis JD, Healey JS, Brueckmann M, Fraessdorf M, Spyropoulos AC, Wallentin L, et al. Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial. *Thrombosis Research* 2016;**139**:77-81. [MEDLINE: 26916299]

Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. *Circulation* 2011;**123**(21):2363-72. [MEDLINE: 21576658]

Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. *American Heart Journal* 2009;**157**(5):805-10, 810.e1-2. [MEDLINE: 19376304]

Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, et al. Dabigatran and warfarin in vitamin K antagonist-naïve and -experienced cohorts with atrial fibrillation. *Circulation* 2010;**122**(22):2246-53. [MEDLINE: 21147728]

Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.[Erratum appears in Circulation. 2012 Sep 4;126(10):e160 Note: Heidebuchle, Hein [corrected to Heidebuchel, Hein]]. *Circulation* 2012;**126**(3):343-8. [MEDLINE: 22700854]

* Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. *Circulation* 2014;**129**(9):961-70. [MEDLINE: 24323795]

Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. *Circulation* 2012;**125**(13):1605-16. [MEDLINE: 22374183]

Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. *Heart* 2014;**100**(15):1193-200. [MEDLINE: 24794140]

Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with

atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. *Circulation* 2012;**125**(5):669-76. [MEDLINE: 22215856]

Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. *Stroke* 2013;**44**(7):1891-6. [MEDLINE: 23743976]

Hori M, Fukaya T, Kleine E, Reilly PA, Ezekowitz MD, Connolly SJ, et al. Efficacy and safety of dabigatran etexilate vs. warfarin in Asian RE-LY patients according to baseline renal function or CHADS2 score. *Circulation Journal* 2015;**79**(10):2138-47. [MEDLINE: 26248573]

Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. *Circulation* 2013;**128**(21):2325-32. [MEDLINE: 24081972]

Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. *Circulation* 2013;**128**(20):2192-201. [MEDLINE: 24016454]

Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. *Circulation* 2011;**123**(2):131-6. [MEDLINE: 21200007]

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. *Annals of Internal Medicine* 2011;**155**(10):660-7. [MEDLINE: 22084332]

Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. *Circulation* 2013;**127**(13):1404-12. [MEDLINE: 23467860]

Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). *Journal of the American College of Cardiology* 2014;**63**(4):321-8. [MEDLINE: 24076487]

Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaet R, Yang S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. *Circulation* 2012;**126**(19):2309-16. [MEDLINE: 23027801]

Verdecchia P, Reboldi G, Di Pasquale G, Mazzotta G, Ambrosio G, Yang S, et al. Prognostic usefulness of left ventricular

hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). *American Journal of Cardiology* 2014;**113**(4):669-75. [MEDLINE: 24359765]

ROCKET AF Study 2010 {published data only}

Apostolakis S, Lane DA, Banerjee A. Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". *Circulation* 2013;**128**(11):e171. [MEDLINE: 24019451]

Balla SR, Cyr D, Lokhnygina Y, Becker R, Berkowitz S, Breithardt G, et al. Obesity paradox for stroke in patients with atrial fibrillation treated with rivaroxaban and warfarin in the ROCKET AF trial [abstract]. *Journal of the American College of Cardiology* 2014;**63**(12 Suppl 1):A371. [EMBASE: 71406395]

Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). *American Heart Journal* 2015;**170**(4):675-82. [MEDLINE: 26386791]

Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Lokhnygina Y, et al. Patients with native aortic stenosis represent a high-risk subgroup in nonvalvular atrial fibrillation-Results from ROCKET AF [abstract]. *European Heart Journal* 2014;**35**:1033. [EMBASE: 71650613]

Breithardt G, Bode C, Patel M, Becker R, Hacke W, Halperin J, et al. Comparison of rivaroxaban with warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation: rationale and design of the ROCKET AF study [abstract]. *Hamostaseologie* 2010;**30**(1):A38. [EMBASE: 70867883]

Capucci A, Prisco D. The ROCKET AF study [Lo studio ROCKET AF]. *Giornale Italiano di Cardiologia* 2012;**13**(9):553-6. [MEDLINE: 22825339]

Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, et al. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF.[Erratum appears in *Circulation*. 2016 Aug 23;134(8):e114; PMID: 27550973]. *Circulation* 2016;**134**(1):37-47. [MEDLINE: 27358435]

Fox KA, Kevorkian JP. ROCKET-AF: data on rivaroxaban in patients with moderate renal function impairment [abstract] [ROCKET-AF: donnees avec le rivaroxaban chez les patients avec alteration moderee de la fonction renale]. *Archives des Maladies du Cœur et des Vaisseaux - Pratique* 2012;**18**(205 Suppl 1):9-10. [EMBASE: 365094155]

* Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. *European Heart Journal* 2011;**32**(19):2387-94. [MEDLINE: 21873708]

Girgis IG, Patel MR, Peters GR, Moore KT, Mahaffey KW, Nessel CC, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. *Journal of Clinical Pharmacology* 2014;**54**(8):917-27. [MEDLINE: 24668660]

Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonist for prevention of stroke and embolism trial in atrial fibrillation). *Journal of the American College of Cardiology* 2014;**63**(9):891-900. [MEDLINE: 24315894]

Goodman SG, Wojdyla DM, White HD, Piccini JP, Paolini JF, Nessel CC, et al. Predictors of major bleeding risk: Insights from the rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonist for prevention of stroke and embolism trial in atrial fibrillation (Rocket AF) [abstract no: 16903]. *Circulation* 2011;**124**(21 Suppl 1). [EMBASE: 70619385]

Greco C. Rivaroxaban in non valvular atrial fibrillation: subgroups analysis [Rivaroxaban nella fibrillazione atriale non valvolare: l'importanza dei sottogruppi]. *Monaldi Archives for Chest Disease* 2014;**82**(1):16-9. [MEDLINE: 25481935]

Hacke W, Hankey G. Rivaroxaban versus warfarin in patients with AF and prior cerebrovascular disease: Results from the ROCKET-AF trial [abstract]. *Cerebrovascular Diseases* 2011;**31**:17. [EMBASE: 70432150]

Halperin JL, Bloomgarden Z, Hellkamp A, Lokhnygina Y, Patel M, Becker R, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: A subgroup analysis of the ROCKET AF trial [abstract no: 15544]. *Circulation* 2012;**126**(21 Suppl 1). [EMBASE: 70956249]

Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). *Circulation* 2014;**130**(2):138-46. [MEDLINE: 24895454]

Halperin JL, Wojdyla D, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET AF trial [abstract no: 148]. *Stroke* 2012;**43**(2 Suppl 1). [EMBASE: 70925131]

Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. *Lancet Neurology* 2012;**11**(4):315-22. [MEDLINE: 22402056]

Hankey GJ, Stevens S, Piccini JP, Lokhnygina Y, Mahaffey KW, Halperin JL, et al. Predictors of intracranial hemorrhage among anticoagulated patients with atrial fibrillation: Insights from the rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF) [abstract no: 152]. *Stroke* 2012;**43**(2 Suppl 1). [EMBASE: 70925135]

Hughey A, Barnes G, Gu X, Haymart B, Kline-Rogers E, Almany S, et al. Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-world" michigan anticoagulation quality improvement initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials [abstract]. *Journal of the American College of Cardiology* 2014;**63**(12 Suppl 1):A418. [EMBASE: 71406442]

Jones WS, Hellkamp AS, Halperin J, Piccini JP, Breithardt G, Singer DE, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. *European Heart Journal* 2014;**35**(4):242-9. [MEDLINE: 24302273]

Jones WS, Hellkamp AS, Halperin J, Piccini JP, Breithardt G, Singer DE, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular-atrial fibrillation: insights from ROCKET AF [abstract]. *European Heart Journal* 2013;**34**(Suppl 1):809-10. [EMBASE: 71260515]

Li HF, Zhao RL. Lack of stroke subtype information may hinder indirect comparison between the ROCKET-AF and other trials of new oral anticoagulants. *Journal of the American College of Cardiology* 2013;**61**(5):595-6. [MEDLINE: 23273400]

Mahaffey KW, Hellkamp A, Patel MR, Hannan K, Schwabe K, Nessel CC, et al. Inadequate anticoagulant therapy during end of study transition to open-label vitamin K antagonist therapy: experience in ROCKET AF [abstract no: 5291]. *European Heart Journal* 2012;**33**(Suppl 1):968. [EMBASE: 70886038]

Mahaffey KW, Hellkamp AS, Patel MR, Hannan KL, Schwabe K, Nessel CC, et al. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. *Circulation. Cardiovascular Quality & Outcomes* 2013;**6**(4):470-8. [MEDLINE: 23759472]

Mahaffey KW, Stevens SR, White HD, Nessel CC, Goodman SG, Piccini JP, et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. *European Heart Journal* 2014;**35**(4):233-41. [MEDLINE: 24132190]

Mahaffey KW, White HD, Nessel CC, Goodman SG, Piccini JP, Patel MR, et al. Ischemic cardiac outcomes in patients with AF treated with vitamin K antagonism or factor Xa inhibition: Results from the ROCKET AF Trial [abstract no: 13482]. *Circulation* 2011;**124**(21 Suppl 1). [EMBASE: 70621217]

Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.[Summary for patients in Ann

Intern Med. 2013 Jun 18;158(12):I-28; PMID: 23778921]. *Annals of Internal Medicine* 2013;**158**(12):861-8. [MEDLINE: 23778903]

Minar E. Presentation of the ROCKET AF study on the occasion of the Annual Congress of the American Heart Association. November 15, 2010, Chicago [abstract] [Presentation der ROCKET-AF-studie anlässlich des Jahreskongresses der American Heart Association 15. November 2010, Chicago]. *Zeitschrift für Gefässmedizin* 2010;**7**(4):18-9. [EMBASE: 360213615]

Nessel C, Mahaffey K, Piccini J, Pan G, Patel M, Becker R, et al. Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: Results from the ROCKET AF trial [abstract]. *Chest* 2012;**142**(4 Suppl 1):84A. [EMBASE: 71072421]

Patel M, Becker R, Breithardt G, Hacke W, Halperin J, Hankey G, et al. Rationale and design of the ROCKET AF study: Comparison of rivaroxaban with warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation [abstract]. *European Heart Journal* 2009;**30**(Suppl 1):705. [EMBASE: 70355859]

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). *Journal of the American College of Cardiology* 2013;**61**(6):651-8. [MEDLINE: 23391196]

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *New England Journal of Medicine* 2011;**365**(10):883-91. [MEDLINE: 21830957]

Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC, et al. Management of major bleeding events in patients treated with rivaroxaban versus warfarin: Results from the ROCKET AF trial [abstract]. *Circulation* 2013;**128**(22 Suppl 1). [EMBASE: 71337075]

Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC, et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. *European Heart Journal* 2014;**35**(28):1873-80. [MEDLINE: 24658769]

Piccini JP, Harrell F, Lokhnygina Y, Wang J, Oppenheimer L, Patel MR, et al. Relationship between center time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial [abstract no: 5293]. *European Heart Journal* 2012;**33**(Suppl 1):968-9. [EMBASE: 70886040]

Piccini JP, Hellkamp AS, Lokhnygina Y, Patel MR, Harrell FE, Singer DE, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. *Journal of the American Heart Association* 2014;**3**(2):e000521. [MEDLINE: 24755148]

Piccini JP, Stevens S, Lokhnygina Y, Patel M, Singer D, Halperin J, et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial [abstract no: 19281]. *Circulation* 2012;**126**(21 Suppl 1). [EMBASE: 70958434]

Piccini JP, Stevens S, Patel MR, Singer DE, Breithardt G, Hankey GJ, et al. Independent predictors of mortality in patients with non-valvular atrial fibrillation: results from ROCKET AF [abstract]. *European Heart Journal* 2012;**33**(Suppl 1):56-7. [EMBASE: 70882618]

Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF. *Circulation* 2013;**127**(2):224-32. [EMBASE: 368158325]

Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". *Circulation* 2013;**128**(11):e172-3. [MEDLINE: 24019452]

Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. *Journal of the American College of Cardiology* 2013;**61**(19):1998-2006. [MEDLINE: 23500298]

Piccini JP, Stevens SR, Patel MR, Mahaffey KW, Paolini JF, Nessel CC, et al. Renal dysfunction is a potent predictor of stroke and systemic embolism among individuals with atrial fibrillation: results from the Rocket AF trial [abstract no: 17137]. *Circulation* 2011;**124**(21 Suppl 1). [EMBASE: 70619386]

Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. *Journal of the American Heart Association* 2016;**4**(3):e002197. [MEDLINE: 26955859]

ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. *American Heart Journal* 2010;**159**(3):340-7. [MEDLINE: 20211293]

Rasty S, Soliman W, Taheri R. Comparative efficacy and safety analysis of atrial fibrillation patients treated with dabigatran in RE-LY study (Chads 2 score of 3 or greater) versus rivaroxaban in ROCKET-AF [abstract]. *Value in Health* 2012;**15**(7):A362. [EMBASE: 70916436]

Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin

K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). *Circulation* 2014;**129**(18):1850-9. [MEDLINE: 24552831]

Sherwood MW, Jones S, Cyr D, Becker R, Berkowitz S, Washam J, et al. The use of dual antiplatelet therapy and patient outcomes in those undergoing PCI in the ROCKET AF trial [abstract]. *Journal of the American College of Cardiology* 2014;**63**(12 Suppl 1):A1724. [EMBASE: 71407748]

Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. *Journal of the American College of Cardiology* 2015;**66**(21):2271-81. [MEDLINE: 26610874]

Singer DE, Hellkamp AS, Halperin JL, Mahaffey KW, Becker RC, Breithardt G, et al. Individual and regional determinants of time in therapeutic range among patients randomized to warfarin in the ROCKET AF trial of rivaroxaban [abstract no: 16169]. *Circulation* 2011;**124**(21 Suppl 1). [EMBASE: 70621620]

Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. *Journal of the American Heart Association* 2013;**2**(1):e000067. [MEDLINE: 23525418]

Spencer RJ, Amerena JV. Rivaroxaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: clinical implications of the ROCKET AF Trial and its subanalyses. *American Journal of Cardiovascular Drugs* 2015;**15**(6):395-401. [MEDLINE: 26062914]

Steinberg B, Hellkamp A, Lokhnygina Y, Halperin J, Breithardt G, Passman R, et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial [abstract]. *Journal of the American College of Cardiology* 2014;**63**(12 Suppl 1):A327. [EMBASE: 71406351]

Steinberg BA, Hellkamp AS, Lokhnygina Y, Halperin JL, Breithardt G, Passman R, et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. *Heart Rhythm* 2014;**11**(6):925-32. [MEDLINE: 24833235]

Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. *European Heart Journal* 2015;**36**(5):288-96. [MEDLINE: 25209598]

Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, et al. Higher risk of death and stroke in patients with persistent versus paroxysmal atrial fibrillation: results from the ROCKET AF trial [abstract]. *European Heart Journal* 2014;**35**:866. [EMBASE: 71649978]

Tiefenbacher CP. ROCKET AF. *Herz* 2011;**36**(2):149-50. [EMBASE: 21424349]

Ugucioni M, Napoletano C. Critical issues in megatrials on new oral anticoagulants. Rocket AF: Applying results to low

risk patients [Questioni aperte nei grandi trial clinici sui nuovi anticoagulanti orali lo studio ROCKET-AF: trasferibilità dei risultati nei soggetti a basso rischio]. *Monaldi Archives for Chest Disease* 2013;**80**(1):3-6. [MEDLINE: 23923584]

Van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Halperin JL, et al. Rivaroxaban is associated with a reduced risk of thromboembolic events and hemorrhagic stroke in patient with heart failure: insights from ROCKET AF [abstract no: 14365]. *Circulation* 2012;**126**(21 Suppl 1). [EMBASE: 70958827]

Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, et al. Digoxin use in patients with atrial fibrillation is associated with adverse cardiac outcomes: results from the ROCKET AF trial [abstract]. *European Heart Journal* 2014;**35**:867. [EMBASE: 71649980]

Wong KS, Hu DY, Oomman A, Tan RS, Patel MR, Singer DE, et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. *Stroke* 2014;**45**(6):1739-47. [MEDLINE: 24763930]

van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. *Circulation: Heart Failure* 2013;**6**(4):740-7. [MEDLINE: 23723250]

References to studies excluded from this review

Caluwé 2016 {published data only}

Caluwé R, Pyfferoen L, De Boeck K, De Vriese AS. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. *Clinical Kidney Journal* 2016;**9**(2):273-9. [MEDLINE: 26985380]

Eriksson 2003a {published data only}

Eriksson UG, Johansson S, Attman PO, Mulec H, Frison L, Fager G, et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. *Clinical Pharmacokinetics* 2003;**42**(8):743-53. [MEDLINE: 12846595]

Koretsune 2015 {published data only}

Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment. *Circulation Journal* 2015;**79**(7):1486-95. [MEDLINE: 25925842]

Murray 2004 {published data only}

Murray PT, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell J, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. *Kidney International* 2004;**66**(6):2446-53. [MEDLINE: 15569338]

References to ongoing studies

X-NOAC Study 2015 {published data only}

Suzuki M, Fukamizu S, Oyama J, Mizukami A, Matsumura A, Hashimoto Y, et al. Rationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: the X-NOAC study. *International Journal of Cardiology* 2015;**188**:52-3. [MEDLINE: 25889327]

Additional references

Alonso 2011

Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 2011;**123**(25):2946-53. [MEDLINE: 21646496]

Bruins Slot 2013

Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. *Cochrane Database of Systematic Reviews* 2013, Issue 8. [DOI: [10.1002/14651858.CD008980.pub2](https://doi.org/10.1002/14651858.CD008980.pub2)]

Dahal 2016

Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. *Chest* 2016;**149**(4):951-9. [MEDLINE: 26378611]

EHRA-EACTS 2010

European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). [Erratum appears in *Europace*. 2011 Jul;13(7):1058 Note: Dosage error in article text]. *Europace* 2010;**12**(10):1360-420. [MEDLINE: 20876603]

EMA 2014

European Medicines Agency. Product-information requirements. 2014. www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000199.jsp (accessed 9 August 2017).

Eriksson 2011

Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. *Annual Review of Medicine* 2011;**62**:41-57. [MEDLINE: 21226611]

FDA 2014

US Food, Drug Administration. 2014 Safety alerts for Human medical products. [www.wayback.archive-it.org/7993/20170111132857/http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm380008.htm](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm380008.htm) (accessed 9 August 2017).

Gage 2001

Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001;**285**(22):2864-70. [MEDLINE: 11401607]

Go 2001

Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001;**285**(18):2370-5. [MEDLINE: 11343485]

Go 2009

Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. *Circulation* 2009;**119**(10):1363-9. [MEDLINE: 19255343]

GRADE 2008

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;**336**(7650):924-6. [MEDLINE: 18436948]

Hart 2007

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Annals of Internal Medicine* 2007;**146**(12):857-67. [MEDLINE: 17577005]

Health Canada 2017

Health Canada. First Nations and Inuit Health. www.canada.ca/en/health-canada/services/first-nations-inuit-health.html (accessed 9 August 2017).

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557-60. [MEDLINE: 12958120]

Higgins 2011

Higgins JP, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

KDIGO 2012

National Kidney Foundation. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney International - Supplement* 2013;**3**(1):1-150. [DOI: [10.1038/kisup.2012.73](https://doi.org/10.1038/kisup.2012.73)]

Lau 2016

Lau YC, Proietti M, Guiducci E, Blann AD, Lip GY. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. *Journal of the American College of Cardiology* 2016;**68**(13):1452-64. [MEDLINE: 27659468]

Levey 2006

Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.[Erratum appears in *Ann Intern Med*. 2008 Oct 7;149(7):519]. *Annals of Internal Medicine* 2006;**145**(4):247-54. [MEDLINE: 16908915]

Levey 2009

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate.[Erratum appears in *Ann Intern Med*. 2011 Sep 20;155(6):408]. *Annals of Internal Medicine* 2009;**150**(9):604-12. [MEDLINE: 19414839]

Liu 2015

Liu G, Long M, Hu X, Hu CH, Liao XX, Du ZM, et al. Effectiveness and safety of warfarin in dialysis patients with atrial fibrillation: a meta-analysis of observational studies. *Medicine* 2015;**94**(50):e2233. [MEDLINE: 26683937]

Marinigh 2011

Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. *Journal of the American College of Cardiology* 2011;**57**(12):1339-48. [MEDLINE: 21414530]

Masson 2015

Masson P, Webster AC, Hong M, Turner R, Lindley RI, Craig JC. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. *Nephrology Dialysis Transplantation* 2015;**30**(7):1162-9. [MEDLINE: 25681099]

Miller 2012

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. *American Journal of Cardiology* 2012;**110**(3):453-60. [MEDLINE: 22537354]

Mitchell 2013

Mitchell SA, Simon TA, Raza S, Jakouloff D, Orme ME, Lockhart I, et al. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis. *Clinical & Applied Thrombosis/Hemostasis* 2013;**19**(6):619-31. [MEDLINE: 23698729]

Nelson 2012

Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in Medicare patients. *Journal of the American Heart Association* 2012;**1**(4):e002097. [MEDLINE: 23130165]

Ng 2013

Ng KP, Edwards NC, Lip GY, Townend JN, Ferro CJ. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. *American Journal of Kidney Diseases* 2013;**62**(3):615-32. [MEDLINE: 23746378]

Olsen 2012

Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease.[Erratum appears in *N Engl J Med*. 2012 Dec 6;367(23):2262]. *New England Journal of Medicine* 2012;**367**(7):625-35. [MEDLINE: 22894575]

Reinecke 2013

Reinecke H, Engelbertz C, Schabitz WR. Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants. *Stroke* 2013;**44**(10):2935-41. [MEDLINE: 24008579]

Schünemann 2011a

Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Schünemann 2011b

Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Soliman 2010

Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC).[Erratum appears in *Am Heart J*. 2010 Dec;160(6):1190], [Erratum appears in *Am Heart J*. 2011 Oct;162(4):794]. *American Heart Journal* 2010;**159**(6):1102-07. [MEDLINE: 20569726]

Stangier 2008

Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. *Clinical Pharmacokinetics* 2008;**47**(1):47-59. [MEDLINE: 18076218]

Stewart 2001

Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. *Heart* 2001;**86**(5):516-21. [MEDLINE: 11602543]

Watson 2009

Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. *Lancet* 2009;**373**(9658):155-66. [MEDLINE: 19135613]

References to other published versions of this review

Kimachi 2014

Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuhara S. New oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients

with chronic kidney disease. *Cochrane Database of Systematic Reviews* 2014, Issue 11. [DOI: [10.1002/14651858.CD011373](https://doi.org/10.1002/14651858.CD011373)]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

ARISTOTLE Study 2010

Methods	<ul style="list-style-type: none"> Study design: double-blind, double-dummy RCT Study duration: 19 December to 2 April 2010 Median duration of study follow-up: 1.8 years
Participants	<ul style="list-style-type: none"> Countries: Australia, China, Hong Kong, India, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Norway, Poland, Romania, Russia, South Africa, Spain, Sweden, Switzerland, Turkey, UK, Ukraine, Argentina, Brazil, Chile, Colombia, Mexico, Peru, Puerto Rico, Canada, USA Setting: multicentre Patients with non-valvular AF; moderate kidney impairment ($25 \leq \text{CrCl} < 50 \text{ mL/min}$); aged ≥ 21 years, and at least one additional risk factors for stroke; age ≥ 75 years; previous stroke, TIA or systemic embolic event; symptomatic heart failure within previous 3 months or left ventricular ejection fraction of no more than 40%; DM; hypertension requiring pharmacologic treatment Number: treatment group (1502); control group (1515) Relevant health status: participants Mean age $\pm$ SD: 77.6 ± 7.1 years Sex (M/F): 1408/1609 Exclusion criteria: AF due to a reversible cause; moderate or severe mitral stenosis; conditions other than AF that required anticoagulation (e.g. a prosthetic heart valve); stroke within the previous 7 days; need for aspirin at a dose of $> 165 \text{ mg/d}$ or for both aspirin and clopidogrel; severe kidney insufficiency ($\text{SCr} > 221 \mu\text{mol/L}$ or calculated $\text{CrCl} < 25 \text{ mL/min}$)
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Oral apixaban: either 2.5 mg or 5 mg twice/d, with dosage determined according to whether participants satisfied two or more of the following criteria: (i) age of at least 80 years; (ii) body weight of no more than 60 kg; or (iii) $\text{SCr} \geq 133 \mu\text{mol/L}$ <p>Control group</p> <ul style="list-style-type: none"> Oral warfarin: dose-adjusted (target INR 2.0 to 3.0)
Outcomes	<ul style="list-style-type: none"> All strokes and systemic embolic events All-cause mortality Major bleeding Intracranial haemorrhage
Notes	<ul style="list-style-type: none"> Funding sources: Bristol-Myers Squibb and Pfizer

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned to treatment groups according to the stratification by clinical site and prior VKA use, and the possibility that this method give the influence on the results was low
Allocation concealment (selection bias)	Low risk	Allocation was concealed because participants were assigned to each group using the Interactive Voice Response System

ARISTOTLE Study 2010 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy design
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Efficacy and safety outcomes were adjudicated on the basis of prespecified criteria by a clinical events committee whose members were unaware of study group assignments
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Primary efficacy outcome was analysed in ITT population. Primary safety outcome was analysed in modified ITT population including all randomised patients who received least one dose of the study drug and included all events from receipt of the study drug until 2 days after the last dose of the drug. It has unclear risk because the number of participants that discontinued during study was reported, but the reason was unclear
Selective reporting (reporting bias)	Low risk	All predefined efficacy and safety outcomes were reported
Other bias	High risk	The study was funded by Bristol-Myers Squibb and Pfizer

ENGAGE AF-TIMI 48 Study 2013

Methods	<ul style="list-style-type: none"> Study design: double-blind, double-dummy RCT Study duration: 19 November 2008 to 22 November 2010 Median duration of study follow-up: 2.8 years
Participants	<ul style="list-style-type: none"> Countries: USA, Canada, Argentina, Brazil, Chile, Colombia, Mexico, Peru, Guatemala, Belgium, Finland, France, Germany, Greece, Israel, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, UK, Denmark, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Poland, Romania, Russia, Serbia and Montenegro, Slovakia, Ukraine, Australia, China, India, Korea, New Zealand, Philippines, South Africa, Taiwan, Thailand, Japan Relevant health status: participants aged ≥ 21 years with non-valvular AF, moderate kidney impairment ($30 \leq \text{CrCl} < 50$ mL/min); a score of 2 or higher on the CHADS₂ risk assessment Setting: multicentre Number: treatment group (1379); control group (1361) Median age (IQR): 79 years (75 to 83) Sex(M/F): 1260/1480 Exclusion criteria: AF due to a reversible disorder; an estimated CrCl < 30 mL/min; a high risk of bleeding; use of dual antiplatelet therapy; moderate-to-severe mitral stenosis; other indications for anticoagulation therapy; acute coronary syndromes, coronary revascularization, or stroke within 30 days before randomisation; an inability to adhere to study procedures
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Oral edoxaban: 30 mg/d <p>Control group</p> <ul style="list-style-type: none"> Oral warfarin: dose-adjusted (target INR 2.0 to 3.0)
Outcomes	<ul style="list-style-type: none"> All strokes and systemic embolic events MI All-cause mortality Major bleeding

ENGAGE AF-TIMI 48 Study 2013 (Continued)

- Minor bleeding
- GI bleeding
- Intracranial haemorrhage

Notes • Funding source: Daiichi Sankyo Pharma Development

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned to treatment groups with the use of a central, 24-hour, interactive, computerized response system
Allocation concealment (selection bias)	Low risk	Allocation was concealed because participants were assigned to each group using a central, 24-hour, interactive, computerized response system
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy design
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Efficacy and safety outcomes were adjudicated by an independent clinical end-point committee whose members were not aware of study group assignments
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Primary efficacy outcome was reported in both ITT and modified ITT population. Primary safety outcome was analysed in modified ITT population. The number of participants that discontinued during study was reported, but the reason was unclear
Selective reporting (reporting bias)	Low risk	All predefined efficacy and safety outcomes were reported
Other bias	High risk	The study was funded by Daiichi Sankyo Pharma Development

J-ROCKET AF Study 2012

Methods	<ul style="list-style-type: none"> • Study design: double-blind, double-dummy RCT • Study duration: 8 June 8 2007 to 19 January 2010 • Median duration of study follow-up: 2.5 years
Participants	<ul style="list-style-type: none"> • Country: Japan • Setting: Multicentre • Participants with non-valvular AF, moderate kidney impairment ($30 \leq \text{CrCl} < 50 \text{ mL/min}$); aged ≥ 20 years, and at least one additional risk factors: a history of prior ischaemic stroke, TIA, or non-CNS systemic embolism, or had ≥ 2 of the following risk factors for thromboembolism, congestive heart failure and/or left ventricular ejection fraction $\leq 35\%$, hypertension, age ≥ 75 years, or DM • Number: treatment group (141); control group (143) • Median age, IQR (years): treatment group (78, 74 to 81), control group (78, 75 to 82) • Sex(M/F): treatment group (105/36); control group (95/48) • Exclusion criteria: $\text{CrCl} < 30 \text{ mL/min}$
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> • Oral rivaroxaban: 10 mg/d

J-ROCKET AF Study 2012 (Continued)

Control group

- Oral warfarin: dose-adjusted (target INR 2.0 to 3.0 for age < 70 and 1.6 to 2.6 to patients for age ≥ 70)

Outcomes	<ul style="list-style-type: none"> • All strokes and systemic embolic events (not shown because of the result from modified ITT analysis) • Major bleeding • Minor bleeding • Intracranial haemorrhage
Notes	<ul style="list-style-type: none"> • Funding source: the Bayer Healthcare Pharmaceuticals Japanese subsidiary, Bayer Yakuhin

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Study was described as randomised, method of randomisation was not reported
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Efficacy and safety outcomes were adjudicated on the basis of prespecified criteria by an independent clinical endpoint committee whose members were unaware of study group assignments
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Primary efficacy endpoints were analysed in the per-protocol population whose were ITT patients with no major protocol violation. Primary safety endpoints were analysed in modified ITT population. The number of participants that discontinued during study was reported, but the reason was unclear
Selective reporting (reporting bias)	Low risk	All predefined efficacy and safety outcomes were reported
Other bias	High risk	The study was funded by the Bayer Healthcare Pharmaceuticals Japanese subsidiary, Bayer Yakuhin

RE-LY Study 2009

Methods	<ul style="list-style-type: none"> • Study design: parallel RCT • Study duration: 22 December 2005 to 15 March 2009 • Median duration of study follow-up: 2.0 years
Participants	<ul style="list-style-type: none"> • Country: Taiwan, Colombia, Mexico, Peru, Romania, India, Russia, Brazil, China, Korea, Greece, Thailand, Malaysia, Poland, Japan, South Africa, France, Slovakia, Portugal, Israel, Czech Republic, Philippines, Bulgaria, Hungary, Hong Kong, Turkey, Belgium, Austria, USA, Spain, Germany, Switzerland, Singapore, Argentina, Netherlands, Norway, Canada, Italy, Ukraine, UK, Denmark, Australia, Finland, Sweden • Setting: multicentre • Relevant health status: participants with non-valvular AF, moderate kidney impairment ($30 \leq \text{CrCl} < 50 \text{ mL/min}$); aged ≥ 18 years, and at least one of the following risk factors for stroke; previous stroke or TIA, a left ventricular ejection fraction of less than 40%, New York Heart Association class II or higher

RE-LY Study 2009 (Continued)

heart-failure symptoms within 6 months before screening, and an age of at least 75 years or an age of 65 to 74 years plus DM, hypertension, or coronary artery disease

- Number: treatment group (2428); control group (1126)
- Mean age $\pm$ SD: 75.2 $\pm$ 7.2 years
- Sex (M/F): 1803/1571
- Exclusion criteria: presence of a severe heart-valve disorder; stroke within 14 days or severe stroke within 6 months before screening; a condition that increased the risk of haemorrhage; CrCl < 30 mL/min; active liver disease; pregnancy

Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> • Oral dabigatran: 110 mg or 150 mg twice daily <p>Control group</p> <ul style="list-style-type: none"> • Oral warfarin: dose-adjusted (target INR 2.0 to 3.0)
Outcomes	<ul style="list-style-type: none"> • All strokes and systemic embolic events • All-cause mortality • Major bleeding (not included in this review because of the result from conventional ITT analysis) • Intracranial haemorrhage (not included in this review because of the result from conventional ITT analysis)
Notes	<ul style="list-style-type: none"> • Funding source: Boehringer Ingelheim Pharmaceuticals

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned to treatment groups with means of a central, interactive, automated telephone system
Allocation concealment (selection bias)	Low risk	Allocation was concealed because participants were assigned to each group using a central, interactive, automated telephone system
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Dabigatran was administered in a blinded fashion, but warfarin was administered in an unblinded fashion. But we judged that incomplete blinding didn't give influence for the outcomes, because the outcomes were objective measures and the outcome assessors were blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Each primary and secondary outcome event was adjudicated by two independent investigators who were unaware of the treatment assignments
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	All outcomes were analyses in the ITT population. The information about discontinuation during study was unclear
Selective reporting (reporting bias)	Low risk	All predefined efficacy and safety outcomes were reported
Other bias	High risk	The study was funded by Boehringer Ingelheim Pharmaceuticals

ROCKET AF Study 2010

Methods	<ul style="list-style-type: none"> • Study design: double-blind, double-dummy RCT
---------	--

ROCKET AF Study 2010 (Continued)

- Study duration: 18 December 2006 to 17 June 2009
- Median duration of study follow-up: 1.9 years

Participants	<ul style="list-style-type: none"> • Countries: Australia, China, Hong Kong, India, Korea, Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand, Bulgaria, Czech Republic, Greece, Hungary, Lithuania, Poland, Romania, Russia, Turkey, Ukraine, Argentina, Brazil, Chile, Colombia, Mexico, Panama, Peru, Venezuela, Canada, USA, Austria, Belgium, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, Norway, South Africa, Spain, Sweden, Switzerland, UK • Setting: multicentre • Participants with non-valvular AF, moderate kidney impairment ($30 \leq \text{CrCl} < 50 \text{ mL/min}$); aged ≥ 18 years, and a score of 2 or higher on the CHADS₂ risk assessment • Number: treatment group (1474); control group (1476) • Median age, IQR (years): treatment group (79; 75 to 82); control group (79, 75 to 83) • Sex (M/F): treatment group (663/811); control group (651/825) • Exclusion criteria: cardiovascular-related conditions; haemorrhage risk-related criteria; any stroke within 14 days before randomisation; TIA within 3 days before randomisation; indication for anticoagulant therapy for a condition other than AF; anaemia at the screening visit; pregnancy or breastfeeding; calculated CrCl $< 30 \text{ mL/min}$; known significant liver disease
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> • Oral rivaroxaban: 15 mg/d <p>Control group</p> <ul style="list-style-type: none"> • Oral warfarin: dose-adjusted (target INR 2.0 to 3.0)
Outcomes	<ul style="list-style-type: none"> • All strokes and systemic embolic events • Major bleeding • GI bleeding • Intracranial haemorrhage
Notes	<ul style="list-style-type: none"> • Funding sources: Johnson & Johnson Pharmaceutical Research & Development L.L.C. (Raritan, NJ) and Bayer HealthCare Pharmaceuticals (Berlin, Germany)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned to treatment groups with the use of a central 24-hour, computerized, automated voice-response system
Allocation concealment (selection bias)	Low risk	Allocation was concealed because participants were assigned to each group using a central 24-hour, computerised, automated voice-response system
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy design
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Efficacy and safety outcomes were adjudicated by an independent clinical end-point committee whose members were unaware of study group assignments
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Primary efficacy outcome was reported in both ITT and modified ITT population. Primary and secondary safety outcome was analysed in the modified ITT population

ROCKET AF Study 2010 *(Continued)*

Selective reporting (re-reporting bias)	Low risk	All outcomes were analyses in the ITT population. The number of participants that discontinued during study was reported, but the reason was unclear
Other bias	High risk	The study was funded by Johnson & Johnson Pharmaceutical Research & Development L.L.C. (Raritan, NJ) and Bayer HealthCare Pharmaceuticals (Berlin, Germany)

AF - atrial fibrillation; CNS - central nervous system; CrCl - creatinine clearance; DM - diabetes mellitus; GI - gastrointestinal; INR - international normalised ratio; IQR - interquartile range; ITT - intention to treat; M/F - male/female; RCT - randomised controlled trial; SCr - serum creatinine; SD - standard deviation; TIA - transient ischaemic attack

Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
Caluwé 2016	Wrong intervention: rivaroxaban versus rivaroxaban plus vitamin K2 versus vitamin K antagonist
Eriksson 2003a	Pharmacokinetic/pharmacodynamic RCT of ximelagatran and melagatran
Koretsune 2015	Pharmacokinetic/pharmacodynamic RCT of 3 treatment regimens of edoxaban
Murray 2004	Pharmacokinetic/pharmacodynamic cross-over RCT of 3 treatment regimens of argatroban

RCT - randomised controlled trial

Characteristics of ongoing studies *[ordered by study ID]*

X-NOAC Study 2015

Trial name or title	Efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: The X-NOAC study
Methods	<ul style="list-style-type: none"> Parallel RCT (1:1)
Participants	<ul style="list-style-type: none"> Non-valvular AF patients with eGFR < 30 and < 89 mL/min/1.73 m² Randomisation factors were age (< 75 years or ≥ 75 years), gender, anticoagulation pretreatment (none or warfarin), and the CHADS₂ score (< 2 or ≥ 2). The total sample size is 160 patients
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Oral rivaroxaban: 15 mg once daily after a meal. In addition, in cases where the CrCl was 30 to 49 mL/min, 10 mg was given orally once daily after a meal <p>Control group</p> <ul style="list-style-type: none"> Warfarin: dose was adjusted such that PT-INR would become 2.0 to 3.0 in patients aged < 70 years or 1.6 to 2.6 in those aged ≥ 70 years
Outcomes	<ul style="list-style-type: none"> The primary endpoint is the change in urinary albumin excretion, and the secondary endpoints are changes in endothelial cell function, blood coagulation/fibrinolysis, inflammation, and kidney function three months after registration
Starting date	<ul style="list-style-type: none"> Not reported
Contact information	Makoto Suzuki, Department of Cardiology, Kameda Medical centre, 929 Higashi-chou, Kamogawa-city, Chiba 296-8602, Japan.

X-NOAC Study 2015 (Continued)

macmed33@gmail.com

Notes

AF - atrial fibrillation; eGFR - estimated glomerular filtration rate; RCT - randomised controlled trial

DATA AND ANALYSES
Comparison 1. Direct oral anticoagulants versus warfarin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All strokes and systemic embolic events	5	12545	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.65, 1.00]
2 Ischaemic stroke	4	8991	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.75, 1.36]
3 Haemorrhagic stroke	4	8991	Risk Ratio (M-H, Random, 95% CI)	0.52 [0.28, 0.97]
4 Major bleeding	5	12521	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.59, 1.04]
5 Myocardial infarction	1	2740	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.45, 1.90]
6 Minor bleeding	2	3012	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.58, 1.61]
7 Gastrointestinal bleeding	2	5678	Risk Ratio (M-H, Random, 95% CI)	1.40 [0.97, 2.01]
8 Intracranial haemorrhage	5	12521	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.69]
9 All-cause mortality	4	9595	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.78, 1.05]

Analysis 1.1. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 1 All strokes and systemic embolic events.

Analysis 1.2. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 2 Ischaemic stroke.

Analysis 1.3. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 3 Haemorrhagic stroke.

Analysis 1.4. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 4 Major bleeding.

Analysis 1.5. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 5 Myocardial infarction.

Analysis 1.6. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 6 Minor bleeding.

Analysis 1.7. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 7 Gastrointestinal bleeding.

Analysis 1.8. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 8 Intracranial haemorrhage.

Analysis 1.9. Comparison 1 Direct oral anticoagulants versus warfarin, Outcome 9 All-cause mortality.

Comparison 2. Direct oral anticoagulants versus warfarin: subgroup analysis for participants with CrCl 30 to 50 mL/min

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All strokes and systemic embolic events	5	12155	Risk Ratio (M-H, Random, 95% CI)	0.82 [0.66, 1.02]
2 Major bleeding	5	12132	Risk Ratio (M-H, Random, 95% CI)	0.80 [0.62, 1.03]

Analysis 2.1. Comparison 2 Direct oral anticoagulants versus warfarin: subgroup analysis for participants with CrCl 30 to 50 mL/min, Outcome 1 All strokes and systemic embolic events.

Analysis 2.2. Comparison 2 Direct oral anticoagulants versus warfarin: subgroup analysis for participants with CrCl 30 to 50 mL/min, Outcome 2 Major bleeding.

Comparison 3. Direct oral anticoagulants versus warfarin: subgroup analysis for participants with CrCl 15 to 30 mL/min

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All strokes and systemic embolic events	2	390	Risk Ratio (M-H, Random, 95% CI)	0.68 [0.23, 2.00]
2 Major bleeding	1	268	Risk Ratio (M-H, Random, 95% CI)	0.30 [0.11, 0.80]

Analysis 3.1. Comparison 3 Direct oral anticoagulants versus warfarin: subgroup analysis for participants with CrCl 15 to 30 mL/min, Outcome 1 All strokes and systemic embolic events.

Analysis 3.2. Comparison 3 Direct oral anticoagulants versus warfarin: subgroup analysis for participants with CrCl 15 to 30 mL/min, Outcome 2 Major bleeding.

Comparison 4. Direct oral anticoagulants versus warfarin: subgroup analysis for different doses of DOAC

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All strokes and systemic embolic events	5	12545	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.65, 1.00]
2 Major bleeding	5	12521	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.63, 1.03]
3 All-cause mortality	4	9595	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.78, 1.05]

Analysis 4.1. Comparison 4 Direct oral anticoagulants versus warfarin: subgroup analysis for different doses of DOAC, Outcome 1 All strokes and systemic embolic events.

Analysis 4.2. Comparison 4 Direct oral anticoagulants versus warfarin: subgroup analysis for different doses of DOAC, Outcome 2 Major bleeding.

Analysis 4.3. Comparison 4 Direct oral anticoagulants versus warfarin: subgroup analysis for different doses of DOAC, Outcome 3 All-cause mortality.

Comparison 5. Direct oral anticoagulants versus warfarin: adverse events

Outcome or sub-group title	No. of studies	No. of participants	Statistical method	Effect size
1 Epistaxis	2	3234	Risk Difference (M-H, Random, 95% CI)	-0.05 [-0.22, 0.11]
2 Nasopharyngitis	2	3234	Risk Difference (M-H, Random, 95% CI)	0.03 [-0.06, 0.11]
3 Diarrhoea	2	3234	Risk Difference (M-H, Random, 95% CI)	0.01 [-0.04, 0.06]
4 Upper respiratory tract inflammation	2	3234	Risk Difference (M-H, Random, 95% CI)	-0.01 [-0.02, 0.01]
5 Back pain	2	3234	Risk Difference (M-H, Random, 95% CI)	-0.02 [-0.05, 0.01]

Outcome or sub-group title	No. of studies	No. of participants	Statistical method	Effect size
6 Cardiac failure	2	3234	Risk Difference (M-H, Random, 95% CI)	-0.01 [-0.03, 0.01]

Analysis 5.1. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 1 Epistaxis.

Analysis 5.2. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 2 Nasopharyngitis.

Analysis 5.3. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 3 Diarrhoea.

Analysis 5.4. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 4 Upper respiratory tract inflammation.

Analysis 5.5. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 5 Back pain.

Analysis 5.6. Comparison 5 Direct oral anticoagulants versus warfarin: adverse events, Outcome 6 Cardiac failure.

Comparison 6. Direct oral anticoagulants versus warfarin: fixed-effect model

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All strokes and systemic embolic events	5	12545	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.65, 1.01]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2 Major bleeding	5	12521	Risk Ratio (M-H, Fixed, 95% CI)	0.79 [0.67, 0.92]

Analysis 6.1. Comparison 6 Direct oral anticoagulants versus warfarin: fixed-effect model, Outcome 1 All strokes and systemic embolic events.

Analysis 6.2. Comparison 6 Direct oral anticoagulants versus warfarin: fixed-effect model, Outcome 2 Major bleeding.

ADDITIONAL TABLES

Table 1. Recommendation of major regulatory agencies

	Dabigatran	Apixaban	Rivaroxaban	Edoxaban
EMA 2014	150 mg twice daily for CKD stage G3 (CrCl 30 to 50 mL/min)	2.5 mg twice daily in patients with at least two of the following characteristics:	15 mg daily for CKD stage G3 and G4 (Cr-Cl 15 to 50 mL/min)	30 mg once daily for CKD stage G3

Table 1. Recommendation of major regulatory agencies *(Continued)*

	No recommendation for CKD stage G4	- age $\geq$ 80 years - body weight $\leq$ 60 kg - SCr > 1.5 mg/dL		and G4 (CrCl 15 to 50 mL/min)
FDA 2014	150 mg twice daily for CKD stage G3 (CrCl > 30 mL/min) 75 mg twice daily for CKD stage G4 (CrCl 15 to 30 mL/min)	2.5 mg twice daily in patients with at least two of the following characteristics: - age $\geq$ 80 years - body weight $\leq$ 60 kg - SCr > 1.5 mg/dL	15 mg daily for CKD stage G3 and G4 (CrCl 15 to 50 mL/min)	30 mg once daily for CKD stage G3 and G4 (CrCl 15 to 50 mL/min)
Health Canada 2017	110 or 150 mg twice daily for CKD stage G3 (CrCl 30 to 50 mL/min) No recommendation for CKD stage G4	2.5 mg twice daily in patients with at least two of the following characteristics: - age $\geq$ 80 years - body weight $\leq$ 60 kg - SCr > 1.5 mg/dL	15 mg daily for CKD stage G3 (CrCl 30 to 50 mL/min) No recommendation for CKD stage G4	30 mg once daily for CKD stage G3 (CrCl 30 to 50 mL/min)

CKD - chronic kidney disease; CrCl - creatinine clearance; SCr - serum creatinine

APPENDICES

Appendix 1. Electronic search strategies

Database	Search terms
CENTRAL	<ol style="list-style-type: none"> 1. "atrial fibrillation":ti,ab,kw 2. "auricular fibrillation":ti,ab,kw 3. {or #1-#2} 4. (new near/3 anticoagulant*):ti,ab 5. dabigatran:ti,ab,kw 6. apixaban:ti,ab,kw 7. rivaroxaban:ti,ab,kw 8. edoxaban:ti,ab,kw 9. (thrombin next inhibit*):ti,ab,kw 10. ((factor next xa next inhibit*) or (factor next 10a next inhibit*)):ti,ab,kw 11. MeSH descriptor: [Anticoagulants] this term only 12. MeSH descriptor: [Factor Xa] this term only 13. #11 and #12 14. MeSH descriptor: [Factor Xa] explode all trees and with qualifiers: [Antagonists & inhibitors - AI] 15. {or #4-#10, #13-#14} 16. {and #3, #15}
MEDLINE	<ol style="list-style-type: none"> 1. Atrial Fibrillation/ 2. atrial fibrillation.tw. 3. auricular fibrillation

(Continued)

4. or/1-3
5. (new adj3 anticoagulant*).tw.
6. dabigatran.tw,rn.
7. apixaban.tw,rn.
8. rivaroxaban.tw,rn.
9. edoxaban.tw,rn.
- 10.direct thrombin inhibit*.tw.
- 11.Anticoagulants/ and Factor Xa/
- 12.factor xa inhibit*.tw.
- 13.Factor Xa/ai
- 14.or/5-13
- 15.and/4,14

EMBASE

1. exp heart atrium fibrillation/
2. atrial fibrillation.tw.
3. auricular fibrillation.tw.
4. or/1-3
5. (new adj3 anticoagulant*).tw.
6. dabigatran/
7. apixaban/
8. rivaroxaban/
9. edoxaban/
- 10.dabigatran.tw.
- 11.apixaban.tw.
- 12.rivaroxaban.tw.
- 13.edoxaban.tw.
- 14.exp blood clotting factor 10a inhibitor/
- 15.exp thrombin inhibitor/
- 16.direct thrombin inhibit*.tw.
- 17.factor Xa inhibit*.tw.
- 18.or/5-17
- 19.and/4,18

Appendix 2. Risk of bias assessment tool

Potential source of bias	Assessment criteria
Random sequence generation	<i>Low risk of bias:</i> Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).
Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence	<i>High risk of bias:</i> Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.
	<i>Unclear:</i> Insufficient information about the sequence generation process to permit judgement.
Allocation concealment	<i>Low risk of bias:</i> Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequential-

(Continued)

<p>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</p>	<p>ly numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</p> <hr/> <p><i>High risk of bias:</i> Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</p> <hr/> <p><i>Unclear:</i> Randomisation stated but no information on method used is available.</p>
<p>Blinding of participants and personnel</p> <p>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</p>	<p><i>Low risk of bias:</i> No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</p> <hr/> <p><i>High risk of bias:</i> No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</p> <hr/> <p><i>Unclear:</i> Insufficient information to permit judgement</p>
<p>Blinding of outcome assessment</p> <p>Detection bias due to knowledge of the allocated interventions by outcome assessors.</p>	<p><i>Low risk of bias:</i> No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</p> <hr/> <p><i>High risk of bias:</i> No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</p> <hr/> <p><i>Unclear:</i> Insufficient information to permit judgement</p>
<p>Incomplete outcome data</p> <p>Attrition bias due to amount, nature or handling of incomplete outcome data.</p>	<p><i>Low risk of bias:</i> No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</p> <hr/> <p><i>High risk of bias:</i> Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; 'as-treated' analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</p> <hr/> <p><i>Unclear:</i> Insufficient information to permit judgement</p>
<p>Selective reporting</p> <p>Reporting bias due to selective outcome reporting</p>	<p><i>Low risk of bias:</i> The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</p> <hr/> <p><i>High risk of bias:</i> Not all of the study's pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse</p>

(Continued)

effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear: Insufficient information to permit judgement

Other bias

-Funding bias

Low risk of bias: The trial was independently funded by a government organization or universities etc.

High risk of bias: The trial was funded by the commercial support and we are sure that there is an important risk of bias.

Unclear: The trial did not declare its funding source, or the trial was funded by the commercial support and we are not sure whether there is an important risk of bias.

CONTRIBUTIONS OF AUTHORS

1. Drafted the protocol: MK, TAF, KK, YG, S Fukuhara
2. Study selection: MK, KK, YG
3. Extracted data from studies: MK, KK, YG
4. Entered data into RevMan: MK, KK
5. Carried out the analysis: MK, KK, YG
6. Interpreted the analysis: MK TAF, KK, YG, S Fukuma, S Fukuhara
7. Drafted the final review: MK, TAF, KK, YG,
8. Disagreement resolution: MK, TAF
9. Updated the review: MK

DECLARATIONS OF INTEREST

- Miho Kimachi: none known
- Toshiaki Furukawa has received lecture fees from Eli Lilly, Janssen, Meiji, Mitsubishi-Tanabe, MSD and Pfizer. He has received royalties from Igaku-Shoin and Nihon Bunka Kagaku-sha publishers. He has received research support from Mitsubishi-Tanabe and Mochida. These funds are not related to the production of this review.
- Kimihiko Kimachi: none known
- Yoshihito Goto: none known
- Shingo Fukuma: none known
- Shunichi Fukuhara: none known

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We changed the terms "NOACs (New oral anticoagulants)" to "DOAC (direct oral anticoagulants)" in accordance with the recommendation of the International Society on Thrombosis and Haemostasis (ISTH). In the original protocol, we intended to distinguish the effect of DOAC on two efficacy primary outcomes: all strokes and systemic embolic events. However, all included studies reported composite outcomes for all strokes, including ischaemic and haemorrhagic stroke and systemic embolic events; we therefore assessed these as one composite outcome.

INDEX TERMS

Medical Subject Headings (MeSH)

Administration, Oral; Anticoagulants [adverse effects] [*therapeutic use]; Antithrombins [adverse effects] [therapeutic use]; Atrial Fibrillation [*complications]; Dabigatran [adverse effects] [therapeutic use]; Embolism [*prevention & control]; Hemorrhage [chemically induced] [epidemiology]; Pyrazoles [adverse effects] [therapeutic use]; Pyridines [adverse effects] [therapeutic use]; Pyridones [adverse effects] [therapeutic use]; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic [*complications]; Rivaroxaban [adverse effects] [therapeutic use]; Stroke [*prevention & control]; Thiazoles [adverse effects] [therapeutic use]; Warfarin [adverse effects] [therapeutic use]

MeSH check words

Humans